jpm

See risk analysis

Cross-Vector Contradictions (4): The triangulation stage identified conflicting signals across independent analytical vectors:

Cross-check: signals remain mixed across the current inputs.

Unique Signals (Single-Vector Only)

financial analysis

elite economics

Financial Analysis overview. Revenue: $182.45B (vs $177.56B prior year) · Net Income: $57.05B (vs -2.4% YoY growth) · EPS: $20.02 (vs +1.4% YoY growth).

Revenue

$49.8B

Q1 2026 reported (+10% YoY)

Net Income

$16.5B

Q1 2026 (+13% YoY, +27% QoQ)

EPS

$5.94

Q1 diluted (+17% YoY)

Debt/Equity

0.74

derived ratio

Net Margin

31.3%

derived ratio

ROE

19%

Q1 2026

Base Fair Value

$330

vs $306 current price

Bull Value

$391

deterministic scenario

Bear Value

$250

deterministic scenario

Position

Neutral

conviction 62/100

Conviction

62/100

cash-flow data gap lowers confidence

ROA

1.3%

FY2025

Rev Growth

+2.8%

Annual YoY

NI Growth

-2.4%

Annual YoY

EPS Growth

+20.0%

Annual YoY

P/BV

2.18x

FY2025

Important takeaway. JPM's most important non-obvious financial signal is that per-share earnings held up better than absolute profit because capital return offset slower growth. FY2025 net income declined 2.4% year over year, yet diluted EPS still increased 1.4% to $20.02, helped by shares outstanding falling from 2.80B to 2.70B. That means the financial story is shifting from pure operating growth to a mix of franchise durability and disciplined repurchases.

Metric	Value
Revenue	$158.10B
Revenue	$177.56B
FY2025 revenue	$182.45B
Key Ratio	12.3%
Net income	$57.05B
Net margin	31.3%
Net margin	15.7%
Net income	$14.64B

Profitability remains elite, but the growth cadence is maturing

Balance-sheet strength is solid for a money-center bank, though leverage crept higher

Cash-flow analysis is constrained, and classic FCF metrics are low-quality for this bank

Capital return is doing real work, but buyback efficacy depends on sustaining premium returns

Key risk. The biggest financial risk is not current profitability but the combination of slower growth and a softer earnings exit rate. Revenue growth slowed to +2.8% in FY2025, and derived Q4 net income fell to about $13.03B versus $14.99B in Q2, suggesting the run-rate entering 2026 was weaker than the full-year headline implies. If expense growth or credit costs rise from here, the market may become less willing to support 2.18x book.

Accounting quality view: mostly clean, with one important limitation. No material audit or revenue-recognition red flag is visible in the supplied filings data, and stock-based compensation was only 2.0% of revenue, which is not a distortion concern. The caution is that the snapshot contains no audited cash flow statement line items, so cash-flow-based outputs such as operating cash flow and implied FCF margins should be treated carefully; for this bank, earnings and book-value metrics are more reliable than the reported -$147.782B operating cash flow figure.

We are Neutral on the financial profile, but only moderately so: our base fair value is $330 per share, with a $391 bull case and $250 bear case, versus a live price of $306. The core reason is that JPM is still generating 15.7% ROE and $57.05B of annual net income while reducing share count, which supports a premium multiple and a Neutral stance with 62/100 conviction. We would turn more cautious if the earnings exit rate weakened further, if ROE slipped materially below the current premium-justifying level, or if better capital and cash-flow disclosures showed the balance sheet to be less resilient than the present filings suggest.

Revenue ($B)
Chart data available in source JSON.

Net Income ($B)
Chart data available in source JSON.

See earnings scorecard

Net Income Trend
Chart data available in source JSON.

Return on Equity Trend
Chart data available in source JSON.

Line Item	FY2022	FY2023	FY2024	FY2025
Revenues	$128.7B	$158.1B	$177.6B	$182.4B
Net Income	$37.7B	$49.6B	$58.5B	$57.0B
EPS (Diluted)	$12.09	$16.23	$19.75	$20.02
Net Margin	29.3%	31.3%	32.9%	31.3%

TOTAL DEBT

$334.7B

LT: $269.9B, ST: $64.8B

NET DEBT

$55.9B

Cash: $278.8B

INTEREST EXPENSE

$24.4B

Annual

Component	Amount	% of Total
Long-Term Debt	$269.9B	81%
Short-Term / Current Debt	$64.8B	19%
Cash & Equivalents	($278.8B)
Net Debt	$55.9B

Total Debt Trend
Chart data available in source JSON.

valuation

probability-weighted fair value

Valuation overview. Base DCF Fair Value: $330 (5-year projection) · 12M Target: $340 · WACC: 10.1% (CAPM-derived) · Terminal Growth: 3.0%.

DCF Fair Value

$330

5-year projection

Enterprise Value

$781.9B

DCF

WACC

10.1%

CAPM-derived

Terminal Growth

3.0%

assumption

DCF vs Current

$330

+7.8% vs current

Parameter	Value
Revenue (base)	$182.45B
FCF Margin	31.3% net margin anchor
WACC	10.1%
Terminal Growth	3.0%
Template	bank equity DCF

DCF Fair Value

$330

Base DCF vs $306 current price

Prob-Wtd Value

$341.21

Scenario-weighted from 4 cases

Current Price

$306

May 28, 2026

Position

Neutral

Quality premium already recognized

Conviction

63/100

Moderate confidence in mid-teens upside

Upside/Downside

+16.4%

Prob-weighted fair value vs current price

Price / Earnings

14.6x

FY2025

Price / Book

2.2x

FY2025

Price / Sales

4.3x

FY2025

EV/Rev

4.3x

FY2025

Important takeaway. JPM still screens modestly undervalued even though growth has slowed, because the market is paying for durability rather than acceleration. The key non-obvious support is that shares outstanding fell from 2.80B to 2.70B while ROE remained 15.7%; that combination lets per-share value compound faster than the headline +2.8% revenue growth would suggest. In other words, the valuation case rests more on capital efficiency and franchise quality than on a re-acceleration in reported revenue.

Method	Fair Value / Implied Value	vs Current Price	Key Assumption
DCF (base)	$330	+7.8%	5-year equity DCF anchored to FY2025 net income of $57.05B, WACC 10.1%, terminal growth 3.0%
DCF (bear)	$250	-18.3%	Margin and growth normalize faster; premium multiple contracts toward lower end of bank range…
Monte Carlo (mean)	-$263.34	-189.8%	Output is economically distorted by bank cash-flow mechanics and is not decision-useful here…
Reverse DCF / market-implied	$306	0.0%	Current price implies the market is underwriting roughly a 30.8% FCF margin, which is awkward for a deposit-funded bank…
Peer P/E calibration	$252.85	-13.8%	Applies cited large-bank peer average P/E of 12.63x to JPM FY2025 diluted EPS of $20.02…

Method selection matters more than usual here. The DCF points to $330, while the Monte Carlo mean shows -$263.34, an obvious mismatch for a bank that earned $57.05B in FY2025. For JPM, valuation should be anchored primarily on earnings, book value, ROE, and capital return rather than industrial-style enterprise cash-flow outputs.

DCF assumptions and why current margins can largely hold

Company / Reference	P/E	P/S	EV/EBITDA	Growth	Margin
JPMorgan Chase	14.6x	4.3x	Not confirmed in source snapshot	+2.8% revenue YoY	31.3% net margin
Large-bank peer average (external reference cited in findings)	14.6x	Not confirmed	Not confirmed	Not confirmed	Not confirmed
Bank of America	Not confirmed in source snapshot	Not confirmed in source snapshot	Not confirmed in source snapshot	Not confirmed in source snapshot	Not confirmed in source snapshot
Citigroup	Not confirmed in source snapshot	Not confirmed in source snapshot	Not confirmed in source snapshot	Not confirmed in source snapshot	Not confirmed in source snapshot
Wells Fargo	Not confirmed in source snapshot	Not confirmed in source snapshot	Not confirmed in source snapshot	Not confirmed in source snapshot	Not confirmed in source snapshot

Peer read-through. The only peer valuation number confirmed in the snapshot is an externally cited 12.63x peer average P/E, versus 14.6x for JPM. That suggests the market already prices JPM as the best house in the neighborhood, so the valuation debate is about sustaining the premium, not discovering a hidden franchise.

Metric	Current	5yr Mean	Std Dev	Implied Value
P/E	14.6x	Not disclosed in source snapshot	Not disclosed	Not calculated from snapshot
P/B	2.18x	Not disclosed in source snapshot	Not disclosed	Not calculated from snapshot
P/S	4.3x	Not disclosed in source snapshot	Not disclosed	Not calculated from snapshot
EV/Revenue	4.3x	Not disclosed in source snapshot	Not disclosed	Not calculated from snapshot
EV/EBITDA	Not confirmed in source snapshot	Not disclosed in source snapshot	Not disclosed	Not calculated from snapshot

Missing history limits a formal reversion test. The snapshot gives exact current multiples, but it does not include 5-year mean or standard deviation data. Practically, that means investors should treat multiple compression risk qualitatively: if growth remains near 2.8% and net income stays below prior momentum, the premium multiple may drift down even without a severe earnings decline.

· bear

$250

· base

$340

· super_bull

$391

· bull

$391

Assumption	Base Value	Break Value	Price Impact	Break Probability
Revenue growth	+2.8% YoY	0.0% to negative growth	Fair value could slide toward $250 bear case (-18.3%)	30%
Diluted EPS	$20.02	$18.00	At 14.6x, implied value falls to $262.80 (-10.4%)	25%
ROE support for premium P/B	15.7%	13.0%	P/B could compress from 2.18x to 1.90x; implied value about $255.06 (-13.0%)	25%
Net margin durability	31.3%	28.0%	Would likely push valuation below base and closer to peer-calibrated $252.85 (-13.8%)	20%
Share-count reduction	2.70B shares	No further buyback support	Less per-share accretion; upside case becomes harder to justify, reducing value by roughly 3% to 5%	35%

Metric	Value
Free cash flow	30.8%
DCF	$330
DCF	$263.34
EPS	$306
EPS	$20.02
Earnings	14.6x
ROE	15.7%
Book	18x

What the market is already implying

Biggest valuation risk. Multiple compression is the main danger, not franchise failure. With revenue growth down to 2.8%, net income growth at -2.4%, and JPM already at 14.6x P/E and 2.18x P/B, even modest normalization toward the cited 12.63x peer P/E would point to roughly $252.85 per share. That is why this is not a clean deep-value setup despite the strong franchise.

Synthesis. Our base DCF fair value is $330, and the probability-weighted scenario value is $341.21, both above the current $306 share price. We give very low weight to the -$263.34 Monte Carlo mean because the source snapshot itself shows that cash-flow-style EV models distort bank economics. Net result: JPM looks modestly undervalued but not materially dislocated; we rate the setup Neutral with 70/100 conviction because a premium franchise is already priced as a premium franchise.

XVARY's differentiated view is neutral-to-mildly bullish: JPM is worth about $341.21 on a probability-weighted basis, or roughly 16.4% above the current price, but that upside is narrower than many quality narratives imply because the stock already trades at 14x earnings and 2.81x TBV. We think the market is correct to award a premium, yet too optimistic if it expects that premium to widen materially while revenue growth sits at only 2.8%. This is bullish for the long-term franchise but only moderately bullish for near-term return potential. We would turn more constructive if the stock fell closer to the $262 to $255 range or if disclosed capital and credit metrics showed that mid-teens ROE can persist with better-than-expected growth; we would turn more cautious if EPS slipped toward $18 without a matching reduction in the valuation multiple.

See financial analysis

See competitive position

· bear

$250

· base

$340

· bull

$391

Component	Value
Beta	0.94
Risk-Free Rate	4.25%
Equity Risk Premium	5.5%
Cost of Equity	9.4%
D/E Ratio (Market-Cap)	0.42
Dynamic WACC	10.1%

Metric	Value
Current Growth Rate	9.2%
Growth Uncertainty	±14.6pp
Observations	13
Year 1 Projected	7.9%
Year 2 Projected	6.8%
Year 3 Projected	6.0%
Year 4 Projected	5.3%
Year 5 Projected	4.7%

Monte Carlo Fair Value Range
Chart data available in source JSON.

Valuation Multiples
Chart data available in source JSON.

what breaks the thesis

falsifiable kill criteria

What Breaks the Thesis overview. Overall Risk Rating: 6.5 / 10 (Premium valuation against slowing growth: P/B 2.18x, P/E 14.6x, EPS growth +1.4%) · # Key Risks: 8 (Ranked in the risk-reward matrix below) · Bear Case Downside: $240.00 (-18.1% vs current price of $306).

Pillar	Invalidating Facts	P(Invalidation)
earnings-power-rate-credit-cycle	JPM's ROTCE falls below a reasonable cost-of-equity range (roughly 11-12%) for at least 4 consecutive quarters excluding clearly one-time items.; Management guidance and reported results show normalized net interest income, fee revenue, and expense levels cannot restore ROTCE above cost of equity within the next 12-24 months.; Credit losses and reserve build demonstrate through-cycle underwriting economics are materially worse than assumed, with net charge-offs and provisions remaining elevated enough to keep returns below cost of equity even after rate normalization.	28%
scale-moat-durability	JPM shows sustained share loss in core deposit, card, payments, or primary banking relationships for at least 4 quarters, indicating scale advantages are no longer protecting customer retention and acquisition.; Incremental competition forces structurally higher deposit pricing, marketing, or technology spend such that JPM's efficiency ratio and spread economics deteriorate without offsetting volume gains.; Peer banks or nonbanks match JPM's product breadth/distribution sufficiently to compress returns in multiple core businesses at once, proving the scale moat is no longer translating into superior profitability.	24%
regulatory-capital-complexity-overhang	Regulatory capital requirements rise durably enough that JPM must operate with materially higher CET1 and cannot return excess capital at levels consistent with its historical payout framework.; A major regulatory, legal, compliance, or operational event results in recurring restrictions, large penalties, forced investment, or business limitations that durably reduce earnings power.; Management or regulators indicate complexity-related costs are structurally rising faster than revenue, and the burden lowers sustainable ROTCE and valuation multiples on a lasting basis.	34%
diversification-vs-hidden-concentration	Segment disclosures show a majority of earnings and incremental profit growth are consistently coming from the most cyclical businesses, with other segments failing to offset downturns.; During a normal stress period, consumer banking and CIB weaken simultaneously and firmwide earnings volatility approaches that of more concentrated peers, demonstrating limited diversification benefit.; Cross-cycle results show wealth, payments, asset management, and other fee businesses are insufficient to stabilize returns when credit and capital-markets conditions deteriorate.	31%
bank-native-valuation-mispricing	On updated assumptions for sustainable ROTCE, growth, and payout, JPM screens at or above fair value relative to its own history and high-quality bank peers on P/TBV and earnings-power frameworks.; Book value and tangible book value growth slow enough, or capital return falls enough, that forward shareholder yield plus compounding no longer supports excess returns from the current price.; The market rerates JPM upward to a valuation fully consistent with its sustainable profitability and risk, eliminating any discount implied by bank-native valuation methods.	46%
ai-and-productivity-optionality	After 2-3 years of elevated AI/technology spending, JPM cannot show measurable improvement in headcount productivity, unit costs, cycle times, or revenue conversion attributable to these investments.; Technology and AI expenses continue rising but are absorbed by compliance, infrastructure, and competitive catch-up needs rather than creating operating leverage.; Management disclosures or segment results indicate AI-driven benefits are immaterial relative to JPM's cost base and therefore insufficient to affect consolidated margins or earnings growth.	55%

Overall Risk Rating

6.5 / 10

Premium valuation against slowing growth: P/B 2.18x, P/E 14.6x, EPS growth +1.4%

# Key Risks

Ranked in the risk-reward matrix below

Bear Case Downside

$240.00

-18.1% vs current price of $306

Probability of Permanent Loss

35%

Reflects bear-or-worse path with durable multiple compression

Graham Margin of Safety

2.7%

Blended fair value $301.20 from DCF $330 and relative value $274.38; below 20%

Position / Conviction

70/100

Neutral stance

The non-obvious takeaway is that the thesis can break without a credit event. JPM still reports a strong 15.7% ROE, but that return is being capitalized at a premium 2.81x TBV and 14x earnings even though 2025 EPS grew only 1.4% and implied Q4 diluted EPS fell to $4.64. That combination means the real risk is not solvency first; it is a de-rating from a premium starting point if investors conclude 2025 was near-peak earnings.

Risk Description	Probability	Impact	Mitigant	Monitoring Trigger
ROE normalization drives multiple compression from premium starting point…	High	High	Year-end 2025 ROE of 15.7% and equity of $362.44B provide a strong starting buffer.	ROE falls below 13.0% or price-to-book remains above 2.0x while earnings stall…
Peak earnings risk as 2025 run-rate fades…	High	High	2025 net income still totaled $57.05B and revenue reached $182.45B, so decline starts from strength.	Annual diluted EPS drops below $19.00 or quarterly EPS stays near the implied Q4 level of $4.64…
Regulatory capital pressure limits buybacks and lowers EPS support…	Medium	High	Shares outstanding already fell from 2.80B to 2.70B, showing existing capital-return capacity.	Shares outstanding stop declining or rise above 2.75B…
Balance-sheet leverage sensitivity as liabilities outgrow equity…	Medium	High	Shareholders' equity increased to $362.44B in 2025, partially offsetting asset growth.	Total liabilities-to-equity exceeds 12.0x from the current 11.21x…
Competitive pricing pressure in lending, deposits, and fee pools erodes franchise premium…	Medium	High	Scale and brand should help defend share better than smaller banks.	Annual revenue falls below $180.00B while total assets remain above $4.30T, implying weaker unit economics rather than shrinkage…
Valuation framework breakdown if investors shift away from earnings/book toward cash-flow skepticism…	Medium	Medium	Banks are usually valued on earnings and book value, not on operating cash flow alone.	Market debate increasingly anchors on reported operating cash flow of -$147.782B or reverse DCF implied FCF margin of 30.8%
Management succession or governance drag at a premium valuation…	Low	Medium	JPM still has a deep bench and a highly profitable franchise.	Further disclosure around Daniel Pinto retirement timing or signs of strategic disruption…
Legal and political headline risk creates reputational drag disproportionate to financial cost…	Low	Medium	Current evidence does not confirm direct balance-sheet impairment from the disclosed case.	Expansion of the reported $5B lawsuit, reserve build disclosures, or direct regulatory escalation…

Trigger	Threshold Value	Current Value	Distance to Trigger (%)	Probability	Impact (1-5)
Return profile no longer supports premium valuation: ROE falls below trigger…	< 13.0%	15.7%	17.2%	Medium	5
Underlying earnings normalize lower: annual diluted EPS breaks support…	< $19.00	$20.02	5.1%	Medium	4
Buyback support fades or reverses: shares outstanding rise…	> 2.75B	2.70B	1.9%	Medium	3
Leverage sensitivity increases: total liabilities / equity exceeds trigger…	> 12.0x	11.21x	7.0%	Medium	4
Competitive dynamics worsen: revenue falls despite very large asset base…	Revenue < $180.00B while assets > $4.30T…	Revenue $182.45B; assets $4.42T	1.3%	Medium	4
Acquisition/intangible risk rises: goodwill as share of equity exceeds trigger…	> 18.0%	14.5%	23.6%	Low	2

Biggest risk: premium multiple meets slowing earnings quality. JPM trades at 2.81x TBV and 14x earnings, yet net income fell 2.4% in 2025 and implied Q4 diluted EPS was only $4.64 versus the full-year $20.02. If investors decide that 2025 was a high-water mark rather than a stable base, the stock can re-rate materially lower without any balance-sheet crisis.

Metric	Value
Fair Value	$306
Book	18x
Earnings	14.6x
EPS	15.7%
EPS	13%
Probability	35%
Probability	$40-$55
ROE below	13.0%

Top Risks Ranked by Probability × Impact

Metric	Value
Revenue	$182.45B
Revenue	+2.8%
Net income	$57.05B
EPS	$20.02
Fair Value	$4.64
Book	18x
Earnings	14.6x
Price target	$240.00

Strongest Bear Case: Premium Franchise, Lower Multiple

Maturity Year	Amount	Interest Rate	Refinancing Risk
2026	Not disclosed in the provided snapshot	Not disclosed	Medium
2027	Not disclosed in the provided snapshot	Not disclosed	Medium
2028	Not disclosed in the provided snapshot	Not disclosed	Medium
2029	Not disclosed in the provided snapshot	Not disclosed	Medium
2030+	Not disclosed in the provided snapshot	Not disclosed	Medium

Metric	Value
Net income	$57.05B
ROE	15.7%
Book	18x
Earnings	14.6x
Revenue	$177.56B
Revenue	$182.45B
Q2 2025 net income	$14.99B
Q3 2025 net income	$14.39B

Where the Bull Case Conflicts with the Numbers

Mitigants That Keep the Risk from Becoming a Sell-Now Call

Failure Path	Root Cause	Probability (%)	Timeline (months)	Early Warning Signal	Current Status
Premium multiple unwinds without credit stress…	ROE and EPS normalize below what a 2.18x P/B can support…	35%	6-18	ROE below 13.0%; annual EPS below $19.00…	Watch
Buyback engine stops supporting per-share growth…	Regulatory capital needs or management caution…	25%	6-12	Shares outstanding stop declining or rise above 2.75B…	Watch
Competitive pressure erodes pricing power…	Price war or share contest in loans, deposits, or fee businesses…	20%	12-24	Revenue below $180.00B while assets remain above $4.30T…	Watch
Balance-sheet growth becomes capital inefficient…	Assets and liabilities outpace equity growth again…	25%	6-18	Total liabilities / equity above 12.0x	Watch
Legal or political headline risk damages valuation premium…	Escalation of the reported $5B lawsuit or related scrutiny…	15%	3-12	Expanded litigation disclosures or reserve commentary…	Safe

Risk/reward is only modestly favorable and not clearly well-compensated. Our bull/base/bear values of $391 / $330 / $240.00 with probabilities of 20% / 45% / 35% produce a probability-weighted value of $313.61, only about 7.0% above the current $306. More importantly, the blended Graham fair value is only $301.20, which implies a 2.7% margin of safety; because that is well below the required 20%, the current setup does not adequately compensate investors for the possibility of a durable de-rating.

The thesis breaks first through valuation compression, not balance-sheet failure. At 2.81x TBV and 14x earnings for only +1.4% EPS growth, we view the risk/reward as neutral to mildly bearish despite a DCF of $330. We would change our mind positively if new filings showed enough capital and earnings resilience to keep ROE at or above 15% without relying on further share shrink, or if the stock traded at least 20% below a risk-weighted value. We would turn outright bearish if ROE fell below 13%, annual revenue fell below $180.00B, or shares outstanding rose above 2.75B.

See management

See detailed supplier-power analysis in the Supply Chain / valuation-linked tab.

See catalysts

Anchoring Risk: Dominant anchor class: PLAUSIBLE (53% of leaves). High concentration on a single anchor type increases susceptibility to systematic bias.

TOTAL DEBT

$334.7B

LT: $269.9B, ST: $64.8B

NET DEBT

$55.9B

Cash: $278.8B

INTEREST EXPENSE

$24.4B

Annual

Component	Amount	% of Total
Long-Term Debt	$269.9B	81%
Short-Term / Current Debt	$64.8B	19%
Cash & Equivalents	($278.8B)
Net Debt	$55.9B

Total Debt Trend
Chart data available in source JSON.

fundamentals & operations

unit economics

Fundamentals overview. Revenue: $182.45B (FY2025 vs $177.56B FY2024) · Rev Growth: +2.8% (vs ~12.3% in FY2024 vs FY2023) · Gross Margin: Not meaningful (Bank reporting does not disclose gross margin in snapshot).

Revenue

$182.45B

FY2025 vs $177.56B FY2024

Rev Growth

+2.8%

vs ~12.3% in FY2024 vs FY2023

FCF Margin

30.8%

Reverse DCF implied margin; historical FCF margin not confirmed

Net Margin

31.3%

FY2025 computed ratio

ROE

15.7%

FY2025 computed ratio

DCF FV

$330

vs $306 price; 11.9% upside

Conviction

62/100

Position: Neutral

The non-obvious operating signal is deceleration, not deterioration. JPM still produced $182.45B of FY2025 revenue and a very high 31.3% net margin, but revenue growth slowed to +2.8% from about 12.3% in the prior year. That combination matters because the franchise is still converting scale into exceptional profit, yet the incremental growth rate now depends more on mix, capital return, and operating leverage than on broad-based expansion.

Segment	Revenue	% of Total	Growth	Op Margin	ASP / Unit Economics
Consumer & Community Banking	$76.03B	41.67%	Not disclosed	Not disclosed	High-volume consumer banking/cards franchise; pricing and customer LTV not disclosed…
Commercial & Investment Bank	~$77.12B (derived from 42.27% share × $182.45B total)	42.27%	Not disclosed	Not disclosed	Institutional wallet economics likely fee and spread driven, but not quantified in snapshot…
Corporate / Nonsegment	~$6.91B (derived from 3.79% share × $182.45B total)	3.79%	Not disclosed	Not disclosed	Residual / treasury-like bucket; no unit economics disclosed…
Remaining segments not broken out in snapshot…	~$22.39B (residual)	12.27%	Not disclosed	Not disclosed	Likely Commercial Banking + Asset & Wealth Management, but audited split not provided here…
Total JPM	$182.45B	100.00%	+2.8%	Not disclosed	Scale economics visible in 31.3% net margin and 15.7% ROE…

Core growth lever: the two large operating engines already account for 83.94% of revenue. If Consumer & Community Banking at $76.03B and Commercial & Investment Bank at about $77.12B merely grow at the company’s FY2025 rate of 2.8% through 2027, they would add roughly $8.70B of combined revenue, while total company revenue would rise by about $10.37B to roughly $192.82B. That is scalable, but it also shows why re-acceleration likely requires stronger segment growth than the current consolidated run rate.

Top 3 Revenue Drivers

Concentration Lens	Observable Disclosure	Read-Through	Risk
Named single customer	No named customer revenue concentration disclosed	Large-bank reporting is organized by segment and balance-sheet exposure, not contract revenue by customer	Low direct evidence of single-client revenue dependency in the source snapshot
Top 10 customer revenue	Not disclosed	Not a decision-useful bank disclosure in this snapshot; concentration is better assessed by segment, counterparty, credit, and funding exposures	Low read-through for revenue concentration; disclosure gap remains
Consumer franchise exposure	CCB = $76.03B, or 41.67% of FY2025 revenue	Diversified mass-market banking, card, and deposit relationships; risk is macro and credit sensitivity, not one-customer dependence	Medium segment concentration, low named-customer concentration
Institutional franchise exposure	CIB is about $77.12B, or 42.27% of FY2025 revenue	Relationship-driven institutional engine; risk sits in capital-markets and client-activity cyclicality rather than disclosed contract duration	Medium segment concentration; named-client concentration is unavailable in the filings snapshot
Overall assessment	The real concentration question is business-mix concentration: CCB and CIB together account for 83.94% of revenue	For JPM, concentration is better understood by segment and balance-sheet exposure than by named customers	Moderate segment concentration, low evidence of single-customer concentration

The biggest operating risk is earnings normalization showing up before revenue re-accelerates. FY2025 revenue still grew +2.8%, but net income growth was -2.4%, and quarterly net income eased to an implied $13.03B in Q4 from $14.99B in Q2. Without loan, deposit, NII, expense, or reserve data in the snapshot, investors cannot tell whether this softer exit rate is benign seasonality or an early pressure signal.

Region	Revenue	% of Total	Growth Rate	Currency Risk
United States	Not disclosed	Not disclosed	Not disclosed	Primary business likely USD-dominant, but not quantified…
EMEA	Not disclosed	Not disclosed	Not disclosed	FX and local regulatory risk present, but not quantified…
Asia Pacific	Not disclosed	Not disclosed	Not disclosed	FX and market-activity sensitivity not quantified…
Latin America / Canada	Not disclosed	Not disclosed	Not disclosed	FX and local credit-cycle exposure not quantified…
Overall disclosure status	Geographic revenue split not provided in snapshot…	N/A	N/A	This limits precise currency and regional operating analysis…

Unit Economics: Strong Returns, Limited Disclosure on Inputs

Metric	Value
Branch coverage (directional)	68%
Total assets	$4.42T
Revenue	$182.45B
Net income	$57.05B
ROE	15.7%
Moat durability	10-15 years

Greenwald Moat Assessment

We think the market is still underestimating how much value a dual-engine franchise can preserve even after growth slows: with 83.94% of revenue tied to CIB and CCB, 15.7% ROE, and a DCF fair value of $330 versus a $306 stock price, our 12-month target is $340, bull case $391, bear case $250, and probability-weighted value $341.21; we rate the operations setup Neutral with 63/100 conviction. This is bullish for the thesis because the franchise still converts scale into superior profitability, but it would turn neutral if revenue growth stalled below the FY2024 level of $177.56B on a forward basis or if ROE clearly fell below the current 15.7% without offsetting share-count reduction.

See product & technology

See supply chain

See financial analysis

Revenue Trend
Chart data available in source JSON.

competitive position

moat vs. threats

Competitive Position overview. Market Share: Not disclosed (Source snapshot references market-share datasets but provides no percentages) · Direct Competitors: Multiple (Exact peer count not disclosed; market is clearly multi-firm rather than monopoly) · Moat Score: 7/10 (Scale, regulation, reputation, and switching frictions are meaningful but not fully quantified).

Direct Competitors

Multiple

Exact peer count not disclosed; market is clearly multi-firm rather than monopoly

Moat Score

7/10

Scale, regulation, reputation, and switching frictions are meaningful but not fully quantified

Contestability

Semi-Contestable

Large incumbents share barriers; new entry is hard, but rivalry among incumbents matters

Customer Captivity

Moderate

Switching, search, and reputation are real; hard retention data is not disclosed

Price War Risk

Medium

Opaque pricing reduces daily wars, but deposit/loan competition can compress spreads

2025 Revenue

$182.45B

Up from $177.56B in 2024

2025 Net Margin

31.3%

High absolute profitability for a bank of this scale

2025 Total Assets

$4.42T

Up from $4.00T at 2024 year-end

Most important takeaway. JPM's competitive edge looks more like a protected oligopoly position than a winner-take-all monopoly: the company earned $57.05B on $182.45B of 2025 revenue with $4.42T of assets, but revenue growth slowed to +2.8% and net income growth turned -2.4%. That combination says barriers are real and scale is monetized, yet incremental pricing power is not strong enough to assume permanently rising margins without mean reversion risk.

Metric	JPM	Competitor 1	Competitor 2	Competitor 3
Revenue	$182.45B	Not disclosed in source snapshot	Not disclosed in source snapshot	Not disclosed in source snapshot
Revenue Growth	+2.8%	Not disclosed in source snapshot	Not disclosed in source snapshot	Not disclosed in source snapshot
Gross Margin	Not meaningful / not disclosed for bank reporting…	Not disclosed in source snapshot	Not disclosed in source snapshot	Not disclosed in source snapshot
Op Margin	Not disclosed in source snapshot	Not disclosed in source snapshot	Not disclosed in source snapshot	Not disclosed in source snapshot
Net Margin	31.3%	Not disclosed in source snapshot	Not disclosed in source snapshot	Not disclosed in source snapshot
R&D / Revenue	Not disclosed in source snapshot	Not disclosed in source snapshot	Not disclosed in source snapshot	Not disclosed in source snapshot
P/E	14.6	Not disclosed in source snapshot	Not disclosed in source snapshot	Not disclosed in source snapshot
Market Cap	$810B	Not disclosed in source snapshot	Not disclosed in source snapshot	Not disclosed in source snapshot
Market Share	Not disclosed in source snapshot	Not disclosed in source snapshot	Not disclosed in source snapshot	Not disclosed in source snapshot
Potential Entrants	Primary threat is not de novo banking entry but well-funded fintech / platform entrants into payments, deposits, lending, or wealth interfaces; exact firms not confirmed in source snapshot…	Face licensing, capital, compliance, cybersecurity, and trust barriers; evidence claim cites $100,000-$500,000 setup-related due diligence/infrastructure cost…	Need balance-sheet scale and customer trust to replicate full-service economics…	Would still need to overcome incumbent distribution and reputation…
Buyer Power	Broad customer base implies low concentration at the customer level; leverage comes from rate shopping rather than buyer concentration…	Switching costs are moderate because account migration, documentation, autopay changes, and relationship re-underwriting are frictional…	Pricing power is constrained in commoditized products like deposits and credit, but stronger in advisory/relationship products…	Overall buyer power: Medium

Takeaway. The missing peer rows are themselves informative: the source snapshot is strong enough to prove JPM's enormous scale, but not strong enough to prove a quantified spread over named rivals. That pushes the moat conclusion toward semi-contestable oligopoly rather than unquestioned dominance.

Metric	Value
Total assets	$4.42T
Shareholders' equity	$362.44B
Revenue	$182.45B
Net income	$57.05B

Greenwald Step 1: Contestability Assessment

Mechanism	Relevance	Strength	Evidence	Durability
Habit Formation	Relevant	Moderate	Banking is recurring and embedded in payroll, bill pay, card use, and savings behavior, but no churn metric is disclosed…	Multi-year if accounts are primary
Switching Costs	Highly relevant	Moderate	Changing primary bank often requires account transfer, autopay changes, documentation, and possible re-underwriting; affluent tiers also use relationship bundles. Supporting evidence cite Chase Private Client at $150K minimum and J.P. Morgan Private Client at $750K minimum…	Multi-year; strongest in wealth and treasury relationships…
Brand as Reputation	Highly relevant	Strong	For deposits, lending, custody, and advice, trust matters. JPM's 2025 scale of $4.42T assets and $57.05B net income supports reputation and perceived safety…	Long duration while balance-sheet strength persists…
Network Effects	Partly relevant	Weak	Banking has some ecosystem effects in payments and treasury relationships, but the snapshot provides no direct platform-network metrics…	Limited unless linked to payments rails or merchant acceptance…
Search Costs	Highly relevant	Moderate	Products are complex, fee structures vary, and relationship products require comparison across rates, service, and trust. Snapshot lacks formal survey data but complexity is evident in full-service banking…	Ongoing, especially for businesses and affluent households…
Overall Captivity Strength	Weighted assessment	Moderate	Captivity is strongest in trust, complexity, and relationship switching, but lacks disclosed retention or wallet-share metrics…	Durable but not impregnable

Greenwald Step 2A: Economies of Scale

Dimension	Assessment	Score (1-10)	Evidence	Durability (years)
Position-Based CA	Present but incomplete	7	Moderate customer captivity plus major scale advantages: $4.42T assets, $182.45B revenue, trust/reputation, relationship friction; market-share and retention data not disclosed…	5-10
Capability-Based CA	Strong	7	Organizational complexity, underwriting, risk management, and cross-product execution are likely advantages; quarterly earnings stability supports this, with Q1-Q3 2025 net income between $14.39B and $14.99B…	3-7
Resource-Based CA	Strong	8	Bank charter/regulatory permissions, capital base, balance-sheet capacity, and reputation are difficult to replicate quickly…	5-15
Overall CA Type	Mixed, dominated by position-based and resource-based advantages…	7	JPM has enough captivity plus scale to exceed pure capability status, but evidence is insufficient to call the moat fully unassailable…	5-10

Capability CA Conversion Test

Factor	Assessment	Evidence	Implication
Barriers to Entry	High	JPM scale at $4.42T assets, $362.44B equity, and large compliance/trust requirements limits new-entry pressure…	External price pressure is muted; rivalry shifts to incumbent behavior…
Industry Concentration	Moderate to High, but exact HHI not disclosed…	The market is clearly dominated by large national banks, but the snapshot provides no HHI or top-3 share…	Some coordination is possible, but not provable from snapshot alone…
Demand Elasticity / Customer Captivity	Moderate captivity	Brand/reputation and switching frictions matter, but buyers can still rate-shop deposits, mortgages, and credit…	Undercutting can win flow in commoditized products, limiting margin stability…
Price Transparency & Monitoring	Mixed / product-dependent	Some banking prices are public, but relationship pricing is opaque and negotiated; no direct pricing dataset is disclosed…	Harder to sustain explicit price discipline than in transparent commodity markets…
Time Horizon	Long horizon, patient capital	JPM's scale, steady quarterly profits, and ongoing buybacks suggest durable franchise planning rather than distressed short-term behavior…	Supports rational pricing, especially in relationship businesses…
Conclusion	Industry dynamics favor unstable equilibrium…	High barriers and long horizons support discipline, but opaque pricing and product-level competition prevent clean tacit coordination…	Margins can stay above average, yet product-specific price competition remains periodic…

Pricing as Communication

Metric	Value
FY2023 revenue	$158.10B
FY2024 revenue	$177.56B
FY2025 revenue	$182.45B
2024 total assets	$4.00T
2025 total assets	$4.42T
2024 equity	$344.76B
2025 equity	$362.44B
Net income	$57.05B

JPM's Market Position

Metric	Value
Total assets	$4.42T
Shareholders' equity	$362.44B
To $500,000	$100,000
Fair Value	$150K
Fair Value	$750K

Barriers to Entry and How They Interact

See detailed TAM/SAM/SOM work in the market-size tab.

Factor	Applies (Y/N)	Strength	Evidence	Implication
Many competing firms	Y	Med	This is not a monopoly; multiple large incumbents likely compete, though exact count is not disclosed…	More players make tacit coordination harder…
Attractive short-term gain from defection…	Y	Med	Customers can rate-shop in deposits, cards, mortgages, and some lending products despite switching frictions…	Selective price cuts can still steal flow…
Infrequent interactions	N	Low	Retail and commercial banking involve repeated interactions and recurring pricing decisions rather than one-off projects…	Repeated-game discipline is more feasible…
Shrinking market / short time horizon	N	Low	JPM's steady quarterly profits and capital return suggest a long-duration franchise, not a shrinking end-market panic…	Supports discipline rather than desperate price cutting…
Impatient players	Not confirmed	Low to Med	No distress evidence in snapshot for JPM; peer distress not disclosed…	Limited evidence of forced defection, but cannot rule out product-level aggression…
Overall Cooperation Stability Risk	Y	Med	High barriers support rational pricing, but multi-product rivalry and rate-sensitive customer behavior keep equilibrium fragile…	Expect episodic competition, not permanent price peace…

Key caution. Current profitability may overstate moat strength: 2025 revenue still grew +2.8%, but net income declined -2.4%. When earnings flatten while the franchise remains enormous, it usually means competitive or mix pressure is already offsetting some of the benefit of scale.

Biggest competitive threat. The source snapshot does not confirm a specific named rival with comparable metrics, so the most credible threat is category-level: large incumbent banks and digital financial platforms attacking rate-sensitive products over the next 12-24 months. The attack vector is not likely wholesale customer abandonment; it is gradual erosion of spread economics in commoditized products, which matters because JPM's 2025 revenue growth slowed to +2.8% while net income growth fell to -2.4%.

See related analysis in

We view JPM's competitive position as strong enough to justify above-average profitability, but not strong enough to assume structurally rising margins from here. The key number is $4.42T of assets supporting $57.05B of net income and a 31.3% net margin; that is bullish for franchise durability, and it aligns with the deterministic DCF fair value of $330 versus a current price of $306, implying roughly 11.9% upside. Our stance is Neutral with conviction 70/100, using scenario values of $391 bull, $330 base, and $250 bear. We would turn more cautious if future filings showed continued profit stagnation without corresponding share gains, or if direct evidence emerged that customer retention and funding advantages are weaker than the current scale suggests.

See market size

market size & tam

runway vs. penetration

Market Size & TAM overview. TAM: $4.56T (Practical balance-sheet TAM proxy based on peak total assets at 2025-09-30; year-end assets were $4.42T.) · SAM: $4.42T (Current served asset base at 2025-12-31; this is the best disclosed proxy for JPM's active serviceable market.) · SOM: $182.45B (2025 revenue monetized from the served base, with 31.3% net margin and $57.05B net income.).

TAM

$4.56T

Practical balance-sheet TAM proxy based on peak total assets at 2025-09-30; year-end assets were $4.42T.

SAM

$4.42T

Current served asset base at 2025-12-31; this is the best disclosed proxy for JPM's active serviceable market.

SOM

$182.45B

2025 revenue monetized from the served base, with 31.3% net margin and $57.05B net income.

Market Growth Rate

7.4%

2023-2025 revenue CAGR; latest annual growth slowed to +2.8% in 2025 from +12.3% in 2024.

Takeaway. JPM's practical TAM is already enormous, but the more important point is that growth is maturing faster than scale is expanding. Revenue rose to $182.45B in 2025 and assets ended at $4.42T, yet annual revenue growth slowed sharply to +2.8% from +12.3% the prior year, implying near-term upside depends more on deeper monetization of an existing franchise than on opening materially new end markets.

Segment / Proxy	Current Size	2028 Projected	CAGR / Growth Assumption	Company Share
Consolidated revenue pool	$182.45B	$198.21B	2.8% annualized, using 2025 reported revenue growth as the forward run-rate…	100% of JPM reported revenue base
Balance-sheet capacity proxy	$4.42T year-end assets; $4.56T peak assets in Q3 2025…	$5.96T	10.5% annualized, using 2025 asset growth vs. 2024 year-end…	100% of JPM reported asset base
Equity capital base	$362.44B	$420.78B	5.1% annualized, using 2025 equity growth vs. 2024…	100% of JPM reported equity base
Earnings monetization pool	$57.05B net income	$61.98B	2.8% annualized, held in line with 2025 revenue growth due to limited segment disclosure…	100% of JPM reported earnings base
Per-share revenue capture	$67.67 revenue per share	$73.52	2.8% annualized, using revenue growth as the proxy…	Per-share participation improved as shares fell from 2.80B to 2.70B…
Business-line TAM segmentation	Not disclosed	Not disclosed	Not disclosed	Consumer, commercial, investment banking, markets, and wealth shares are not confirmed in the provided snapshot…

Bottom-up TAM methodology: franchise-scale proxies, not industry hype

Penetration, maturity, and runway

Biggest caution. The market looks huge because assets reached $4.56T at the Q3 2025 peak, but monetization is clearly slowing: revenue growth fell to +2.8% in 2025 from +12.3% in 2024. That combination raises the risk that incremental balance-sheet growth is entering a lower-return, more capital-constrained phase rather than signaling a fresh step-up in real TAM.

TAM risk. JPM's TAM is probably smaller than headline scale suggests if measured by economically attractive, regulator-approved growth rather than raw balance-sheet size. The evidence is that liabilities were $4.06T against $362.44B of equity at 2025 year-end, with 11.21x total liabilities-to-equity, so effective TAM can compress quickly if capital rules tighten or funding conditions worsen even when customer demand remains intact.

We think the right TAM conclusion is neutral-to-bullish: JPM does not need a bigger headline market to work as an investment because it already monetized $182.45B of revenue at a 31.3% net margin in 2025, and our deterministic fair value is $330 versus a live price of $306. The stock is bullish for the thesis if management can keep compounding within the existing served market through returns and buybacks, not if investors rely on an undefined external TAM story. We would change our mind if revenue growth remains stuck around +2.8% while returns deteriorate, or if future filings show weaker capital efficiency and less flexibility than the current $4.42T asset base implies.

See competitive position

product & technology

roadmap + software stack

Product & Technology overview. R&D Spend ($): Not disclosed (No R&D expense line in available filings/source snapshot) · R&D % Revenue: Not disclosed (Cannot compute without disclosed R&D expense; 2025 revenue was $182.45B) · Products/Services Count: 5 core franchises (Consumer & Community Banking, Corporate & Investment Bank, Commercial Banking, Asset & Wealth Management, and enterprise technology/control stack assessed from available filings context).

Products/Services Count

5 core franchises

Consumer & Community Banking, Corporate & Investment Bank, Commercial Banking, Asset & Wealth Management, and enterprise technology/control stack assessed from available filings context

2025 Revenue

$182.45B

Up from $177.56B in 2024; Revenue Growth YoY was +2.8%

2025 Net Income

$57.05B

Supports internal funding capacity for multiyear platform modernization

DCF Fair Value

$330

Vs stock price $306 on May 28, 2026; bull $391, bear $250

XVARY View

Neutral | conviction 70/100

Scale-funded technology durability is modestly bullish, but direct tech KPIs are sparse

Most important takeaway. JPM's product-and-technology edge is best understood through funding capacity rather than disclosed innovation spend. The company generated $182.45B of revenue and $57.05B of net income in 2025 while still posting a 31.3% net margin, which implies management can keep investing in platforms, cybersecurity, and data infrastructure even though direct R&D and technology-expense lines are not disclosed in the available filings.

Product / Service Family	Revenue Contribution ($)	% of Total	Growth Rate	Lifecycle Stage	Competitive Position
Consumer & Community Banking	Not disclosed in source snapshot	Not disclosed	Not disclosed	Mature	Leader
Corporate & Investment Bank	Not disclosed in source snapshot	Not disclosed	Not disclosed	Mature	Leader
Commercial Banking	Not disclosed in source snapshot	Not disclosed	Not disclosed	Mature	Leader
Asset & Wealth Management	Not disclosed in source snapshot	Not disclosed	Not disclosed	Growth	Challenger
Enterprise Payments / Treasury / Data & Risk Infrastructure…	Not disclosed in source snapshot	Not disclosed	Not disclosed	Growth	Leader
Bank-wide digital servicing, fraud, control, and cloud/data modernization…	Not separately monetized or disclosed	Not disclosed	Not disclosed	Growth	Leader in scale, not directly measurable from snapshot…

Takeaway. The portfolio is unquestionably broad, but segment-level revenue by product is not disclosed in this snapshot. For investors, that means the more reliable signal is enterprise earning power and balance-sheet support, not management's product taxonomy.

Technology stack: scale and control are the moat

R&D pipeline: funded internally, but milestones are not disclosed

IP and moat assessment: execution, data, licenses, and trust outweigh disclosed patents

Biggest caution. The largest risk in this pane is disclosure opacity: there is no direct R&D expense, no technology expense, no capex, no digital-user count, and no segment-level product adoption data in the source snapshot. That matters more because revenue growth slowed to +2.8% in 2025 from 12.3% in 2024, so investors increasingly need proof that platform spending is still producing measurable growth or efficiency.

Technology disruption risk. The most credible disruption vector is not a single disclosed competitor metric but the possibility that large-bank peers such as Bank of America, Wells Fargo, or Citigroup improve digital servicing, payments, and data platforms faster than JPM over the next 12-24 months. Probability is moderate: JPM's scale and profitability are major defenses, but the absence of disclosed tech KPIs means underperformance could show up first in slowing revenue productivity rather than in an explicit product metric.

Our differentiated view is that JPM's product-and-technology story is being underwritten by economic capacity, not by transparent innovation disclosure: a bank earning $57.05B on $182.45B of revenue with a 31.3% net margin can keep compounding its platform even in a slower-growth year. Using the deterministic valuation outputs, our $340 target and $330 base fair value frame the stock as neutral-to-bullish for the thesis versus the $306 share price, with $391 bull and $250 bear scenarios. We assign conviction 70/100 because disclosure gaps are meaningful; we would change our mind if growth stayed near the current +2.8% level or weakened further without evidence that technology is improving monetization, or if direct disclosures later showed underinvestment relative to peers.

See competitive position

supply chain

single points of failure

Supply Chain overview. Key Supplier Count: Not disclosed (No vendor list or critical third-party count is provided in the source snapshot.) · Single-Source %: Not disclosed (Supplier-level concentration is not confirmed; the key dependency is funding/liquidity rather than physical sourcing.) · Customer Concentration: Not disclosed (Top-10 customer % of revenue is not provided in the available filings snapshot.).

Lead Time Trend

Stable

Supported by steady quarterly net income of $14.64B, $14.99B, and $14.39B in 2025.

Geographic Risk Score

3.0 / 5

Analyst score: region mix is not disclosed, but operational complexity is elevated at $4.42T of assets.

Funding Dependence Proxy

91.9%

Derived as $4.06T liabilities / $4.42T assets at 2025-12-31.

Important takeaway. For JPM, “supply chain” risk is really a funding-and-infrastructure dependency question, not a physical procurement issue. The clearest evidence is the combination of $4.06T of liabilities against $4.42T of assets at 2025-12-31 and -$147.782B of computed operating cash flow, which means resilience depends more on uninterrupted funding channels, counterparties, and core platforms than on any disclosed raw-material supplier.

Supplier	Component/Service	Revenue Dependency (%)	Substitution Difficulty (Low/Med/High)	Risk Level (Low/Med/High/Critical)	Signal (Bullish/Neutral/Bearish)
Funding markets / wholesale funding channels…	Balance-sheet funding and liquidity continuity…	Not disclosed; balance-sheet proxy shows liabilities at 91.9% of assets…	High	Critical	Bearish
Customer deposit base	Primary operating funding source	Not disclosed	High	High	Neutral
Core payments and settlement infrastructure…	Transaction processing and settlement	Not disclosed	High	High	Neutral
Core banking / cloud / data-center vendors…	Platform uptime and system availability	Not disclosed	High	High	Neutral
Market data and trading connectivity vendors…	Markets pricing, execution, and risk management inputs…	Not disclosed	High	Medium	Neutral
Telecom and network providers	Branch, office, and digital connectivity…	Not disclosed	Medium	Medium	Neutral
Cybersecurity and identity vendors	Fraud control, access management, and resilience…	Not disclosed	High	High	Neutral
Card and merchant acceptance networks	Consumer payment throughput	Not disclosed	Medium	Medium	Neutral
Clearing, custody, and counterparty network…	Trade completion and client asset servicing…	Not disclosed	High	High	Neutral

Relationship / Exposure Bucket	Observable Share / Disclosure	Relationship Structure	Primary Concentration Risk	Trend
Named single customer	No named customer dependence disclosed	Banking franchise, not contract manufacturing; relationships are recurring and are not presented as fixed customer contracts	Low direct customer concentration risk in the source snapshot	Stable
Consumer & Community Banking	$76.03B, or 41.67% of FY2025 revenue	High-volume consumer banking, card, and deposit relationships	Consumer credit and spending slowdown, not contract renewal risk	Stable
Commercial & Investment Bank	About $77.12B, or 42.27% of FY2025 revenue	Relationship-led institutional and capital-markets activity	Capital-markets, advisory, and corporate-activity cyclicality	Stable
Residual businesses / diversification	Roughly 16.06% of revenue sits outside CCB and CIB	Asset & wealth, corporate / other, and residual businesses diversify the franchise	Smaller individually, but disclosure in this snapshot is less granular	Stable
Overall read-through	Customer concentration looks low; segment concentration is the more relevant lens	The franchise is diversified by relationship count, but still concentrated in two giant operating engines	Funding, liquidity, and business-mix concentration matter more than any single disclosed client	Stable

Funding Chain, Not Physical Inputs, Is the Real Concentration Risk

Geographic Exposure Is Undisclosed, So Complexity Must Be Inferred Indirectly

Component	% of COGS	Trend	Key Risk
Liability-funded balance sheet (proxy)	91.9% of assets	Rising vs 91.5% in 2024	High dependence on stable funding and liquidity channels…
Equity support (proxy)	8.2% of assets	Stable to slightly lower vs 8.6% in 2024…	Thin equity share relative to balance-sheet scale increases sensitivity in stress…
Goodwill / acquired intangible burden (proxy)	1.2% of assets	Stable	Low current integration risk; major acquisition-driven disruption not evident…
Stock-based compensation	2.0% of revenue	Not disclosed for prior year in snapshot…	Talent retention and compensation inflation in key control functions…
Net margin retention	31.3% of revenue	Down implied by -2.4% net income growth vs +2.8% revenue growth…	Earnings conversion did not fully keep pace with revenue growth…
Operating cash flow conversion	-81.0% of revenue	Negative	Cash-flow profile raises dependence on external funding flexibility…

Biggest caution. The sharpest supply-chain warning signal is the disconnect between a 30.8% reverse-DCF implied FCF margin and the computed -$147.782B operating cash flow. Even allowing for bank cash-flow noise, that gap suggests investors may be underwriting cleaner self-funding economics than the recent balance-sheet movements actually show.

Single biggest vulnerability. The main single point of failure is the funding and liquidity chain, not a named physical supplier. Based on $4.06T of liabilities, 11.21x liabilities-to-equity, and -$147.782B of computed operating cash flow, I assign roughly a 15% 12-month probability of a material funding or core-platform disruption that could temporarily reduce annual revenue by about 4% before recovery. The likely mitigation timeline is 1-2 quarters through liquidity repricing, balance-sheet normalization, and rerouting of critical transaction flows; exact contingency arrangements are not disclosed in the source snapshot.

Our differentiated view is neutral-to-slightly bullish on JPM’s supply-chain resilience because the market is focusing on vendor opacity while the more important signal is that the franchise remained operationally steady despite carrying a balance sheet funded 91.9% by liabilities and posting -$147.782B of computed operating cash flow. This is neutral for the thesis at the pane level because steady 2025 quarterly net income of $14.64B, $14.99B, and $14.39B argues the network is functioning, but it is not a clean all-clear. At the total-company level, valuation remains supportive with DCF fair value of $330 per share versus a market price of $306, with bull/base/bear values of $391 / $330 / $250; pane conviction is 58/100. We would turn more bearish if new disclosures showed a concentrated outsourced platform or funding source representing more than roughly 10% of operating capacity, or if liabilities expand again without improvement in cash-flow quality.

catalyst map

forward calendar

Catalyst Map overview. Total Catalysts: 10 (8 operating/regulatory; 2 speculative product/partnership items) · Next Event Date: 2026-04-14 (Q1 2026 earnings date is not fully corroborated in the source snapshot, not company-confirmed here) · Net Catalyst Score: +2 (Modestly bullish: capital return and per-share accretion outweigh NII compression risk).

Total Catalysts

8 operating/regulatory; 2 speculative product/partnership items

Next Event Date

2026-04-14

Q1 2026 earnings date is not fully corroborated in the source snapshot, not company-confirmed here

Net Catalyst Score

Modestly bullish: capital return and per-share accretion outweigh NII compression risk

Expected Price Impact Range

-$30.78 to +$34.83

Vs $306 stock price using DCF bear value $250 and base fair value $330

DCF Fair Value

$330

Base-case deterministic fair value; bull $391, bear $250

XVARY Position

Neutral

conviction 71/100

Thesis Conviction

71/100

Good evidence on earnings power and buybacks; weaker evidence on 2026 dates and capital ratios

Most important takeaway. The key catalyst is not simple revenue growth; it is per-share earnings accretion from capital deployment. In 2025, net income fell 2.4% year over year while diluted EPS still rose 1.4% to $20.02, and shares outstanding dropped from 2.80B to 2.70B. That means the next stock-moving events are more likely to be buyback capacity, regulatory capital clarity, and NII stabilization than ordinary top-line beats.

Date	Event	Category	Impact	Probability (%)	Directional Signal
2026-04-14	Q1 2026 earnings release; date is scheduled in the source snapshot but not otherwise confirmed here…	Earnings	High	85%	Neutral to Bullish
Q2 2026 (date not confirmed)	Management commentary on whether NII ex Markets improves from the prior disclosed decline of $185M, or 1%	Earnings	High	80%	Bullish if stabilized; Bearish if worse
Q2 2026 (date not disclosed)	Regulatory capital and repurchase-capacity update; catalyst path supported by the July 1, 2025 capital update evidence…	Regulatory	High	70%	Bullish
Q2 2026	Rate-path and deposit repricing effects on spread income and funding pressure…	Macro	Medium	100%	Neutral	Neutral
Q3 2026 earnings window (date not confirmed)	Q2 2026 earnings release and updated normalized earnings commentary…	Earnings	High	80%	Neutral	Neutral
Q3 2026 (date not disclosed)	Third-quarter dividend and common share repurchase program confirmation, analogous to the July 1, 2025 update…	Regulatory	High	70%	Bullish
H2 2026 (date not confirmed)	Evidence that fee mix is improving through wealth, markets, and payments rather than balance-sheet growth alone…	Earnings	Medium	60%	Bullish
H2 2026 (speculative)	LLM Suite commercialization or measurable operating-productivity disclosures; based on not fully corroborated innovation evidence…	Product	Low	35%	Bullish	Bullish
H2 2026 (speculative)	Strategic partnership monetization with Coinbase, if management discloses revenue or client-growth effects…	Product	Medium	40%	Bullish	Bullish
Q1 2027 earnings window (date not confirmed)	FY2026 results and 2027 outlook; important reset on capital return, normalized ROE, and earnings durability…	Earnings	High	80%	Neutral to Bullish

Date/Quarter	Event	Category	Expected Impact	Bull/Bear Outcome
2026-04-14	Q1 2026 earnings	Earnings	High	Bull: EPS and net income stay near or above 2025 quarterly run-rate; Bear: earnings slip enough to challenge premium multiple…
Q2 2026	NII ex Markets trend check	Earnings	High	Bull: prior -1% pressure flattens or improves; Bear: deposit margin compression persists and offsets scale benefits…
Q2 2026	Capital return and regulatory flexibility update…	Regulatory	High	Bull: continued repurchases reinforce EPS accretion; Bear: tighter capital requirements slow buybacks…
Q2-Q3 2026	Macro rate path and funding-cost reset	Macro	Medium	Bull: lower funding pressure and stronger markets activity; Bear: spread compression worsens faster than fee offset…
Q3 2026	Q2 2026 earnings and outlook refresh	Earnings	High	Bull: management shows normalized earnings durability without one-time items; Bear: growth remains asset-heavy but margin-light…
Q3 2026	Dividend/repurchase program confirmation…	Regulatory	High	Bull: another year of share count reduction similar to 2025 path; Bear: slower capital return weakens per-share thesis…
H2 2026	Wealth, markets, and payments mix improvement…	Earnings	Medium	Bull: better fee intensity supports premium valuation; Bear: balance-sheet growth continues to outpace revenue quality…
H2 2026	Digital/productivity or partnership disclosures…	Product	Low	Bull: technology and partnerships expand efficiency narrative; Bear: no measurable financial impact, leaving thesis dependent on classic banking drivers…
Q1 2027	FY2026 results and 2027 setup	Earnings	High	Bull: annual results support fair value above current price; Bear: premium multiple compresses toward bear case if returns stall…

· bear

$250

· bull

$391

Quarterly Outlook: What to Watch in the Next 1-2 Quarters

Date	Quarter	Consensus EPS	Consensus Revenue	Key Watch Items
2026-04-14	Q1 2026	Not disclosed in source snapshot	Not disclosed in source snapshot	Whether quarterly EPS holds near the 2025 range of $5.07-$5.24; any update on NII ex Markets and capital return…
Q3 2026 window (date not confirmed)	Q2 2026	Not disclosed in source snapshot	Not disclosed in source snapshot	Whether management shows stabilization after the prior disclosed $185M, or 1%, NII ex Markets decline…
Q4 2026 window (date not confirmed)	Q3 2026	Not disclosed in source snapshot	Not disclosed in source snapshot	Repurchase pace, dividend commentary, and evidence that fee businesses are carrying more of the growth mix…
Q1 2027 window (date not confirmed)	Q4 2026 / FY2026	Not disclosed in source snapshot	Not disclosed in source snapshot	Annual earnings durability, share count trend versus 2.70B current level, and 2027 capital-return setup…

Metric	Value
Revenue	$182.45B
Net income	$57.05B
EPS	$20.02
ROE	15.7%
Earnings	14.6x
Book	18x
Buyback	75%
Probability	65%

Value Trap Test: Are the Catalysts Real?

Biggest caution. JPM already trades like a premium franchise at 14.6x P/E and 2.18x price-to-book, so ordinary earnings beats may not be enough to rerate the stock. The other caution is valuation-model quality: the reverse DCF implies a 30.8% FCF margin while computed operating cash flow is -$147.782B and detailed cash-flow disclosure is absent from the SEC snapshot, which means investors should rely more on earnings, capital return, and balance-sheet evidence than on cash-flow-based upside alone.

Highest-risk catalyst event: failure to stabilize spread income after management already disclosed that NII ex Markets fell $185M, or 1%, in Q2 2025. I assign roughly 55% probability that this remains the key debate through Q2-Q3 2026; if upcoming results show another leg down without enough fee offset, downside could be about $15 per share, pushing the stock toward the lower end of its current valuation range. The contingency scenario is that buybacks and balance-sheet strength soften the blow, but the premium multiple would still be vulnerable.

We are Neutral on JPM as a catalyst setup because the market is paying for quality but not fully for continued per-share accretion; our base fair value is $330, or about $34.83 above the current $306 stock price. The differentiated view is that the next move is more about capital deployment than topline growth: a 3.6% share-count reduction in 2025 mattered more than the modest 2.8% revenue growth. We would change our mind if the next 1-2 quarters show renewed NII deterioration without a buyback offset, or if regulatory capital constraints materially slow share reduction and pull the thesis back toward the $250 bear case.

street expectations

consensus vs. framework

Moderate Buy consensus (15 buy, 15 hold, 0 sell) with average target ~$337 (range $295–$391). Key targets: Goldman $361, UBS $375, Evercore $340, Piper Sandler $345. FY26 EPS consensus ~$22.42 (+10.2%).

Current Price

$306

May 28, 2026

Market Cap

$810B

DCF Fair Value

$330

our model

vs Current

+7.8%

DCF implied

Our Target

$340

12-month target vs $306 current price

Difference vs Street

~+$3

Our $340 target vs ~$337 street average

Key takeaway. The most important point is that JPM’s valuation appears to be supported more by durability than by growth acceleration. Audited FY2025 revenue increased only +2.8% to $182.45B and net income declined -2.4% to $57.05B, yet the stock still trades at 14x earnings and 2.81x TBV; that combination implies the market is underwriting sustained returns, not a reacceleration story.

· bear

$250

· base

$340

· bull

$391

Metric	Street Consensus	Our Estimate	Diff %	Key Driver of Difference
Q1 2026 EPS	Not confirmed from available evidence	$4.90	Not computable	Assumes stabilization above implied Q4 2025 EPS of $4.64 but below Q2 2025 peak of $5.24…
FY2026 Revenue	Not confirmed from available evidence	$187.92B	Not computable	Assumes 3.0% growth from FY2025 revenue of $182.45B as franchise momentum persists without reacceleration…
FY2026 Diluted EPS	Not confirmed from available evidence	$20.50	Not computable	Assumes modest earnings growth supported by stable margins and share count discipline near 2.70B…
FY2026 Net Margin	Not confirmed from available evidence	31.0%	Not computable	Assumes profitability remains close to reported 31.3% rather than reverting sharply lower…
Fair Value / Target Price	Not confirmed from available evidence	$330	Not computable	DCF based on 10.1% dynamic WACC and sustained franchise returns…

Year	Revenue Est	EPS Est	Growth %
2023A	$158.10B	Not disclosed in source snapshot	Not disclosed
2024A	$177.56B	Not disclosed in source snapshot	+12.3% revenue
2025A	$182.45B	$20.02	+2.8% revenue / +1.4% EPS
2026E	$187.92B	$20.50	+3.0% revenue / +2.4% EPS
2027E	$194.50B	$21.30	+3.5% revenue / +3.9% EPS

Metric	Value
Revenue growth	+2.8%
Net income	-2.4%
Net income	+1.4%
EPS	$20.02
EPS	$5.07
EPS	$5.24
Fair Value	$4.64
ROE near	15.7%

Revision Trend Read-Through

Primary caution. The sharpest risk in this pane is that the market may be assuming a level of cash-generation quality not directly evidenced in the snapshot. The reverse DCF implies a 30.8% free-cash-flow margin, while the only cash-flow-related figure provided is operating cash flow of -$147.782B; without full cash-flow statement detail, valuation confidence should be tempered.

What would make the Street right and our view wrong? If JPM demonstrates that FY2025 was merely a pause and not a lower-growth regime, specifically by keeping ROE at or above 15.7%, restoring quarterly diluted EPS toward the earlier $5.07-$5.24 range rather than the implied $4.64 Q4 level, and sustaining book-value growth beyond the rise from $344.76B to $362.44B, then the current premium multiple would be justified and our caution on expectations would prove too conservative.

We are Neutral but selective on this pane, with a Neutral stance, conviction 70/100, and a $340 target versus the current $306 price. The setup is constructive because the stock still offers roughly 11.9% upside to our base-case DCF while JPM continues to post strong absolute profitability, including 31.3% net margin and 15.7% ROE. What would change our mind is evidence that the softer FY2025 quarterly run-rate persists, especially if EPS remains near the implied $4.64 Q4 level, ROE slips meaningfully below mid-teens, or future filings fail to support the market’s implied cash-flow normalization.

See Earnings Scorecard

Metric	Current
P/E	14.6
P/S	4.3

Our Quantitative View

earnings scorecard

execution quality

Earnings Scorecard overview. Beat Rate: 1/1 quarters (Only one quarter in the snapshot includes a disclosed consensus EPS comparison: Q4 2025 adjusted EPS beat) · Avg EPS Surprise: +6.1% (Q4 2025 adjusted EPS of $5.23 vs $4.93 consensus in source evidence) · TTM EPS: $20.02 (FY2025 diluted EPS from available filings).

Beat Rate

1/1 quarters

Only one quarter in the snapshot includes a disclosed consensus EPS comparison: Q4 2025 adjusted EPS beat

Avg EPS Surprise

+6.1%

Q4 2025 adjusted EPS of $5.23 vs $4.93 consensus in source evidence

TTM EPS

$20.02

FY2025 diluted EPS from available filings

Latest Quarter EPS

$5.94

Q1 2026 diluted (+17% YoY)

FY2025 Net Income

$16.5B

Q1 2026 net income (+13% YoY)

FY2025 Revenue Growth

+10%

Q1 2026 reported revenue YoY

2026 NII Guide

$103B

Management projection cited in Q4 2025 presentation evidence

DCF Fair Value

$330

Base-case per-share fair value vs stock price of $306

Period	EPS	YoY Change	Sequential
2022-06	$2.76
2022-09	$3.12		+13.0%
2023-03	$4.10		+31.4%
2023-06	$4.75		+15.9%
2023-09	$4.33	+27.8%	-8.8%
2024-03	$4.44	+42.3%	+2.5%
2024-06	$6.12	+49.3%	+37.8%
2024-09	$4.37	-8.0%	-28.6%
2025-03	$5.07	+17.1%	+16.0%
2025-06	$5.24	+18.0%	+3.4%
2025-09	$5.07	-17.2%	-3.2%

Important takeaway. JPM’s headline earnings look stronger than the quarter-by-quarter cadence underneath them. Full-year diluted EPS was $20.02, but the 2025 quarterly sequence was $5.07, $5.24, $5.07, and an implied $4.64, showing that earnings softened into year-end even as management still pointed to $103B of 2026 NII. The non-obvious implication is that investors are paying for durability, not acceleration, so the next print matters more for confirming re-acceleration than for proving baseline profitability.

Quarter / Period	Guidance Range	Actual	Within Range (Y/N)	Error %
Q1 2025	Not disclosed in snapshot	Not disclosed in snapshot	N/A	Not calculable
Q2 2025	Not disclosed in snapshot	Not disclosed in snapshot	N/A	Not calculable
Q3 2025	Not disclosed in snapshot	Not disclosed in snapshot	N/A	Not calculable
Q4 2025	Not disclosed in snapshot	Not disclosed in snapshot	N/A	Not calculable
FY2025 NII (after Q2 update)	About $95.5B	Not disclosed in snapshot	Pending confirmation	Not calculable
FY2026 NII	$103B	Pending period	Pending	N/A

Metric	Value
Revenue	$182.45B
Revenue	$57.05B
Net income	$20.02
EPS	31.3%
EPS	15.7%
EPS	$5.07
EPS	$5.24
Fair Value	$4.64

Earnings Quality: Strong franchise earnings, but Q4 quality was less clean than the headline beat

Metric	Value
FY2025 NII guide	$95.5B
Prior FY2025 NII guide	$94.5B
FY2025 revenue growth	+2.8%
FY2026 NII guide	$103B
Q4 2025 adjusted EPS	$5.23
Q4 2025 EPS consensus	$4.93
NII guide raise	$1.0B
Q4 adjusted EPS beat	+6.1%

Revision Trends: Management raised NII, but external estimate transparency is limited

Metric	Value
FY2025 NII guide	$95.5B
FY2026 NII guide	$103B
FY2025 net income	$57.05B
FY2025 diluted EPS	$20.02
2024 equity	$344.76B
2025 equity	$362.44B
Implied Q4 GAAP EPS	$4.64
Q4 adjusted EPS	$5.23

Management Credibility: High, based on conservative upward guidance behavior and no disclosed restatement issues

Metric	Value
EPS	$5.15
EPS	$5.07
EPS	$5.24
Fair Value	$4.64
2026 NII guide	$103B
FY2025 NII guide	$95.5B
Q2 2025 credit costs	$2.1B
Q4 2025 credit-loss provision	$3.4B

Next Quarter Preview: Watch NII trajectory and credit costs more than the headline EPS print

Caution. The biggest accounting-quality caution is the Q4 2025 gap between filing-derived GAAP diluted EPS of $4.64 and externally cited adjusted EPS of $5.23. That spread suggests one-time or normalization items had a material impact, and the snapshot does not include enough audited line-item detail to fully bridge the difference.

Earnings risk. The line item to watch is credit provisioning. Evidence already shows a $3.4B provision for credit losses in Q4 2025; if that line moves clearly above the recent level rather than reverting, the market is likely to read the quarter as a quality miss even if headline EPS is acceptable. For a stock trading at 14.6x earnings and 2.18x book, a miss driven by higher provisions or a weaker NII outlook could plausibly produce a mid-single-digit share reaction, with roughly 5% to 8% downside on the print.

We think the market is underappreciating how much of the 2025 story was about exit-rate softness rather than franchise deterioration: filing-derived Q4 EPS fell to $4.64, but management still guided to $103B of 2026 NII, and our base-case fair value remains $330 per share versus the current $306. That is bullish for the thesis because it implies about 11.9% upside to base value, with bull and bear values of $391 and $250; we therefore rate the stock Neutral with conviction 70/100. We would change our mind if management cuts the $103B NII framework or if credit provisioning rises enough to show that Q4 was not a one-off quality issue but the start of a lower-earnings regime.

See financial analysis

See street expectations

EPS Trend (Annual)
Chart data available in source JSON.

LATEST EPS

$5.07

Q ending 2025-09

AVG EPS (8Q)

$4.92

Last 8 quarters

EPS CHANGE

$20.02

vs year-ago quarter

TTM EPS

$19.75

Trailing 4 quarters

Quarter	EPS (Diluted)	Net Income
Q2 2023	$4.75	$14.5B
Q3 2023	$4.33	$13.2B
Q1 2024	$4.44	$13.4B
Q2 2024	$6.12	$18.1B
Q3 2024	$4.37	$12.9B
Q1 2025	$5.07	$14.6B
Q2 2025	$5.24	$15.0B
Q3 2025	$5.07	$14.4B

alternative data

outside-in confirmation

Signals overview. Overall Signal Score: 58/100 (Neutral; conviction 58/100. DCF fair value $330 vs price $306 implies 11.9% upside, offset by slower growth and model conflict.) · Bullish Signals: 5 (Strong absolute profitability, ROE 15.7%, share count down to 2.70B, book value support, DCF above market.) · Bearish Signals: 4 (Revenue growth slowed to 2.8%, net income growth -2.4%, implied Q4 EPS fell to $4.64, liabilities/equity 11.21x.).

Overall Signal Score

58/100

Neutral; conviction 58/100. DCF fair value $330 vs price $306 implies 11.9% upside, offset by slower growth and model conflict.

Bullish Signals

Strong absolute profitability, ROE 15.7%, share count down to 2.70B, book value support, DCF above market.

Bearish Signals

Revenue growth slowed to 2.8%, net income growth -2.4%, implied Q4 EPS fell to $4.64, liabilities/equity 11.21x.

Data Freshness

Mixed

Stock price as of May 28, 2026; audited FY2025 financials through Dec 31, 2025. Alternative data and formal sentiment series are not disclosed in the snapshot.

Most important takeaway. The non-obvious signal is that per-share resilience is stronger than underlying profit momentum. Diluted EPS increased to $20.02 in 2025 and the deterministic ratio shows +1.4% EPS growth, but net income growth was -2.4% and shares outstanding fell from 2.80B to 2.70B. That means capital return, not accelerating operating earnings, was the main cushion to the 2025 equity story. If investors begin to focus more on the implied Q4 2025 EPS of $4.64 than on full-year EPS, the signal mix can turn weaker quickly.

Category	Signal	Reading	Trend	Implication
Operating momentum	Revenue growth decelerated	Revenue rose from $177.56B in 2024 to $182.45B in 2025; Revenue Growth YoY +2.8%	Slowing	Still growing, but the pace is now consistent with maturity rather than reacceleration.
Profitability	Absolute earnings remain very strong	2025 net income $57.05B; net margin 31.3%; ROE 15.7%; ROA 1.3%	Stable-to-softening	Core earnings power remains high enough to support a premium multiple if durability holds.
Per-share support	Buybacks cushioned EPS	Diluted EPS $20.02; EPS Growth YoY +1.4%; shares outstanding fell from 2.80B to 2.70B…	Supportive	EPS optics are better than profit growth, which helps sentiment but can mask slower business momentum.
Quarterly earnings	Late-year moderation	2025 net income: Q1 $14.64B, Q2 $14.99B, Q3 $14.39B, implied Q4 $13.03B; diluted EPS: $5.07, $5.24, $5.07, implied $4.64…	Weakening	Direction into year-end was softer; investors may anchor on the lower implied Q4 run-rate.
Balance sheet	Asset growth outpaced equity growth	Total assets increased from $4.00T to $4.42T; shareholders' equity increased from $344.76B to $362.44B…	Expansionary	Higher earning-asset capacity is positive, but balance-sheet expansion raises sensitivity to funding and credit conditions.
Leverage/capital	Highly levered by design	Total liabilities $4.06T; Total Liab/Equity 11.21; Debt/Equity 0.74…	Elevated	Strong profitability offsets leverage today, but this remains the key structural sensitivity.
Valuation	Market price below deterministic DCF	Price $306 vs DCF fair value $330; bull $391; bear $250; P/E 14.6; P/B 2.18…	Constructive	Valuation is supportive for a quality franchise, but upside is moderate rather than deep-value wide.
Model quality	Cash-flow models conflict with earnings/book signals…	Monte Carlo mean -$263.34, median -$222.32, P(Upside) 0.0%; operating cash flow -$147.782B; cash flow statement unavailable…	Conflicted	Treat cash-flow-based outputs as weak evidence for a bank until a bank-specific cash framework is supplied.
Book-value quality	Premium multiple rests on tangible franchise quality…	Shareholders' equity $362.44B; implied book value/share about $134.24; price-to-book 2.18; goodwill $52.73B…	Supportive	Stable goodwill and rising equity make the premium-to-book easier to defend than if intangibles were expanding rapidly.

Metric	Value
Fair Value	$306
Price-to-book	18x
2024 total assets	$4.00T
2025 total assets	$4.42T

Alternative Data Read-Through: Sparse External Signal Set

Metric	Value
Market cap	$306
Market capitalization	$810B
Market capitalization	14.6x
Market capitalization	18x
DCF	11.9%
DCF	$330
EPS	$20.02
EPS	$5.24

Sentiment Indicators: Market Confidence Is Positive, But Not Euphoric

Primary caution. The biggest risk in this pane is that headline EPS stability may be overstating underlying momentum. Net income growth was -2.4% year over year while EPS growth was +1.4%, helped by shares outstanding falling from 2.80B to 2.70B; at the same time, implied Q4 2025 diluted EPS was $4.64, below Q1, Q2, and Q3. If quarterly earnings continue to track closer to the implied Q4 level, the market may reassess the current 14.6x P/E and 2.18x P/B as too generous for a slower-growth phase.

Aggregate signal picture. The balance of evidence is slightly positive but not emphatically bullish. JPM still combines $57.05B of annual net income, 15.7% ROE, rising equity to $362.44B, and a deterministic DCF fair value of $330 against a $306 stock price, which supports downside resilience and modest upside. The offset is that growth has slowed materially, with revenue growth at 2.8%, net income growth at -2.4%, and quarterly earnings easing into year-end. On balance, the signal set supports a Neutral stance with a slight positive bias rather than a high-conviction long.

We are Neutral on JPM on a 12-month signal basis, with conviction 70/100 and a base-case fair value of $330 per share versus the current $306, alongside a $391 bull case and $250 bear case. That is modestly bullish on valuation alone, but the operating signal is less clean because revenue growth slowed to 2.8%, net income growth turned -2.4%, and implied Q4 2025 EPS of $4.64 points to decelerating momentum. Our differentiated view is that the market is correctly paying for durability, but it may be giving too much credit to EPS that was helped by a lower share count from 2.80B to 2.70B. We would turn more bullish if quarterly EPS reaccelerates above the Q2 2025 level of $5.24 or if revenue growth clearly improves from the 2025 run-rate; we would turn bearish if earnings settle around the implied Q4 run-rate and book-value growth no longer offsets the premium valuation.

PIOTROSKI F

5/9

Moderate

Criterion	Result	Status
Positive Net Income	✓	Pass
Positive Operating Cash Flow	✗	Fail
ROA Improving	✓	Pass
Cash Flow > Net Income (Accruals)	✗	Fail
Declining Long-Term Debt	✓	Pass
Improving Current Ratio	✗	Fail
No Dilution	✓	Pass
Improving Gross Margin	✗	Fail
Improving Asset Turnover	✓	Pass

historical analogies & timeline

base rates

JPMorgan Chase currently screens less like a turnaround bank and more like a mature, premium franchise entering a later-cycle normalization phase. The audited record shows a bank still growing from enormous scale, revenue rose from $158.10B in 2023 to $177.56B in 2024 and $182.45B in 2025, but the pattern underneath that growth matters more than the headline. Net income growth turned negative at -2.4% while diluted EPS still increased +1.4% to $20.02, implying that capital return and franchise quality are doing more of the work than operating acceleration. Historically, that setup tends to resemble the best periods of large universal banks: premium valuation can persist, but upside becomes more dependent on sustaining returns and buybacks than on raw balance-sheet expansion.

FAIR VALUE

$330

DCF base case vs $306 stock price

UPSIDE

+7.8%

Base case premium to Mar. 26, 2026 price

BULL / BEAR

$391 / $250

Deterministic scenario values

ROE

15.7%

Supports premium-bank analogy

P/TBV

2.18x

Market still paying for quality at scale

POSITION

Neutral

conviction 70/100

Takeaway. The non-obvious point is that JPM's per-share resilience is stronger than its aggregate earnings trend: 2025 net income growth was -2.4%, but diluted EPS still grew +1.4% to $20.02. That divergence lines up with the decline in shares outstanding from 2.80B at 2024 year-end to 2.70B at 2025 year-end, which means the current historical analog is a capital-return compounder rather than a bank enjoying broad-based operating acceleration.

Analog Company	Era/Event	The Parallel	What Happened Next	Implication for This Company
JPMorgan itself	2024-2025 balance-sheet expansion and earnings normalization…	Assets grew from <strong>$4.00T</strong> at 2024 year-end to a <strong>$4.56T</strong> peak in 3Q25 before ending 2025 at <strong>$4.42T</strong>, while revenue still rose to <strong>$182.45B</strong>.	The pattern suggests a dominant funding and client franchise absorbing flows, but with late-year earnings cooling as implied 4Q25 net income fell to <strong>$13.03B</strong>.	This is a premium-franchise, late-cycle analog. The key question is not survival, but whether more assets convert into sustained returns or simply a larger balance sheet.
Morgan Stanley	Mature premium-bank phase	Useful analog for a large financial institution that wins a higher multiple because investors trust business mix and capital return more than raw revenue growth.	Historically, premium reratings became steadier but less explosive once the market already priced in quality; future stock moves depended on maintaining return metrics rather than narrating reinvention.	JPM at <strong>14.6x P/E</strong> and <strong>2.81x TBV</strong> looks similar in market psychology: upside likely comes from holding a premium, not from a sudden multiple step-change.
Goldman Sachs	Late-cycle earnings plateau at a high-quality franchise…	A top-tier financial institution can still trade well even when revenue grows but incremental earnings momentum softens.	When quarterly cadence loses momentum, investors typically stop paying for acceleration and instead value the company on normalized earnings power.	JPM's annual diluted EPS of <strong>$20.02</strong> implies 4Q25 diluted EPS of <strong>$4.64</strong>, below the first three quarters, so the stock may behave more like a quality compounder than a momentum trade.
Bank of America	Post-repair capital-return compounding	Once a large bank is no longer in repair mode, share count reduction can matter as much as underlying profit growth for per-share value creation.	In that pattern, book value growth and repurchases often drive investor returns more reliably than headline top-line acceleration.	JPM's share count fell from <strong>2.80B</strong> to <strong>2.70B</strong>, so the relevant analog is a scaled bank using excess capital to preserve EPS growth even if net income softens.
Wells Fargo	Premium multiple vulnerable to growth deceleration…	Large banks can keep premium valuations only as long as investors believe returns are durable and regulation or normalization will not erode earnings quality.	Once earnings momentum fades, the valuation premium can compress even if the franchise remains profitable and systemically important.	JPM's <strong>15.7% ROE</strong> justifies a premium today, but the implied 4Q25 slowdown and already-full <strong>2.81x TBV</strong> mean the analog warns against assuming endless multiple expansion.

Lesson from the Morgan Stanley-style premium-compounder analog. When a financial franchise is already viewed as best-in-class, the stock usually rises through steady earnings durability and capital return, not through a dramatic narrative rerating. Applied to JPM, that argues the path from $306 toward the $330 base fair value is plausible if ROE stays near 15.7%, but history does not support expecting a runaway multiple expansion unless earnings growth reaccelerates beyond the current +1.4% EPS growth rate.

Metric	Value
Revenue FY2025	$182.45B
Revenue FY2024	$177.56B
Revenue FY2023	$158.10B
Revenue growth FY2025	+2.8%
Net income growth FY2025	-2.4%
Q1 2025 net income	$14.64B
Q2 2025 net income	$14.99B
Q3 2025 net income	$14.39B

JPM Looks Like a Mature Franchise in Late-Cycle Normalization

Primary caution. The biggest historical risk is that JPM is already moving from premium-growth to premium-normalization faster than the market expects. Annual net income of $57.05B implies 4Q25 net income of only $13.03B, and annual diluted EPS of $20.02 implies 4Q25 diluted EPS of $4.64, both below the first three quarters; if that moderation persists, the current 14.6x P/E and 2.81x TBV could prove closer to peak multiples than durable floors.

Metric	Value
Goodwill 1Q25	$52.62B
Goodwill 2Q25	$52.75B
Goodwill 3Q25	$52.72B
Goodwill FY2025	$52.73B
Net income growth FY2025	-2.4%
EPS growth FY2025	+1.4%
Diluted EPS FY2025	$20.02
Total assets FY2024	$4.00T

Recurring Historical Pattern: JPM Responds Through Scale, Capital Return, and Organic Compounding

We are Neutral on this history setup, but only moderately so: JPM looks like a premium bank in late-cycle normalization, and our base fair value is $330 per share versus a stock price of $306, with a $391 bull case and a $250 bear case. We therefore rate the shares Neutral with conviction 70/100, because a 15.7% ROE, 2.80B to 2.70B share-count reduction, and stable goodwill argue for durable franchise quality rather than a fragile cyclical peak. We would change our mind if ROE materially slipped below the current 15.7% level or if another stretch of quarterly earnings at or below the implied $13.03B 4Q25 run rate suggested that normalization is becoming structural rather than temporary.

See fundamentals

management & leadership

execution + key-person risk

Management & Leadership overview. Management Score: 4.0 / 5.0 (Average of 6-dimension scorecard based on 2025 operating, balance-sheet, and capital-allocation evidence) · Insider Ownership %: Not disclosed (No authoritative ownership table or Form 4 summary is included in the provided snapshot) · Leadership Continuity / Tenure: CEO continuity; board refresh in 2025 (James Dimon as Chairman & CEO per company disclosures; Brad D. Smith joined the board effective 2025-01-21; Michele G. Buck elected to the board effective 2025-03-17 per JPMorgan Chase IR).

Management Score

4.0 / 5.0

Average of 6-dimension scorecard based on 2025 operating, balance-sheet, and capital-allocation evidence

Leadership Continuity / Tenure

CEO continuity; board refresh in 2025

James Dimon as Chairman & CEO; Brad D. Smith effective 2025-01-21; Michele G. Buck effective 2025-03-17 (JPMorgan Chase IR)

Compensation Alignment

Moderate

2025 CEO pay reported at $43M, up 10.3%, but official SEC proxy tables are not included in this snapshot

Most important takeaway. The strongest management signal is capital allocation discipline, not biography: shares outstanding fell from 2.80B at 2024-12-31 to 2.70B at 2025-12-31 even as shareholders' equity increased from $344.76B to $362.44B. That combination helped support +1.4% EPS growth to $20.02 despite -2.4% net income growth, which is unusually strong evidence that management is protecting per-share value rather than merely growing the balance sheet.

Dimon-led team still appears to be building scale advantages, but succession remains the swing factor

Name	Title / Role	Tenure / Date	Background / Status	Key Achievement or Observation
James Dimon	Chairman and Chief Executive Officer	Current tenure not disclosed in snapshot…	Role identified in the supplied leadership evidence rather than a verified officer table in this dataset…	Leadership period covered by 2025 results: revenue $182.45B, net income $57.05B, diluted EPS $20.02…
Brad D. Smith	Director	Effective 2025-01-21	Board refresh addition confirmed in the analytical findings…	Joined during a year in which assets ended at $4.42T and equity rose to $362.44B…
Michele G. Buck	Director	Serving since 2025	Newer board member confirmed in the analytical findings…	Part of 2025 board refresh at a company with $810B market capitalization as of 2026-05-28…
Chief Financial Officer	Not disclosed in snapshot	Not confirmed	No authoritative executive roster or tenure table is included in the provided source set…	Limits direct assessment of finance-lead continuity and capital-markets execution…
Chief Operating Officer / President	Not disclosed in snapshot	Not confirmed	No verified officer-level disclosure is included in the provided source set…	Creates a disclosure gap around succession depth below the CEO-chair level…

Governance is credible on continuity and refresh, but oversight concentration is still real

Metric	Value
Reported 2025 CEO pay package of	$43M
Key Ratio	10.3%
Revenue	$182.45B
Net income	$57.05B
EPS	$20.02
ROE	15.7%
2024 equity	$344.76B
2025 equity	$362.44B

Compensation appears directionally aligned with performance, but official proxy detail is missing here

Dimension	Score (1-5)	Evidence Summary
Capital Allocation	5	Strong evidence of shareholder-focused capital deployment. Shares outstanding declined from 2.80B at 2024-12-31 to 2.70B at 2025-12-31 while shareholders' equity increased from $344.76B to $362.44B. Goodwill was stable between $52.62B at 2025-03-31 and $52.73B at 2025-12-31, implying no large acquisition that diluted discipline.
Communication	3	Management credibility is supported indirectly by stable 2025 quarterly earnings ($14.64B Q1, $14.99B Q2, $14.39B Q3; implied $13.03B Q4), but the snapshot does not include guidance history, earnings-call transcripts, or guidance-vs-actual statistics. Transparency cannot be scored higher without those disclosures.
Insider Alignment	2	No authoritative insider ownership percentage, Form 4 activity summary, or proxy ownership table is included in the snapshot. Alignment is therefore difficult to verify directly, although per-share capital allocation was favorable through the 2.80B to 2.70B share-count reduction.
Track Record	5	Multi-year operating evidence is strong. Revenue rose from $158.10B in 2023 to $177.56B in 2024 and $182.45B in 2025. 2025 net income was $57.05B, diluted EPS was $20.02, ROE was 15.7%, and net margin was 31.3%, showing sustained execution at scale.
Strategic Vision	4	Strategy appears clear: organic growth, balance-sheet stewardship, and capital return rather than transformational M&A. Total assets increased from $4.00T at 2024-12-31 to $4.42T at 2025-12-31 while goodwill remained roughly flat near $52.7B. Board refresh in 2025 also suggests some forward-looking governance adaptation.
Operational Execution	5	Execution remained strong despite a tougher comparison base. 2025 revenue grew 2.8% to $182.45B while net income declined only 2.4% to $57.05B. Quarterly earnings were consistently high, EPS still grew 1.4%, and profitability stayed robust at 31.3% net margin and 15.7% ROE.
Overall weighted score	4.0	Average of the six required dimensions. The score is pulled up by excellent capital allocation, operating execution, and long-term track record, but capped by limited disclosure on insider alignment and communication metrics in the provided source set.

Direct insider alignment cannot be verified from this snapshot

Biggest management risk. Key-person concentration remains the largest governance caution because the evidence still centers on a single Chairman and CEO figure while the company runs a $4.42T asset base and $4.06T of liabilities at 2025-12-31. With total liabilities to equity at 11.21, even a small credibility shock around succession or risk control could matter more here than at a less leveraged business.

Succession planning is the main open question. The supplied evidence says the board is spending significant time on successor development, which is appropriate given $57.05B of 2025 net income and a $810B market cap. But no formal timeline, named successor slate, or officer-level bench disclosure is included in this snapshot, so succession readiness cannot be fully validated.

We are neutral-to-bullish on management and would score the team 4.0/5.0, mainly because capital allocation and execution remained excellent: shares fell by 0.10B year over year while equity rose by $17.68B, supporting $20.02 of 2025 diluted EPS. For the broader stock, our analytical anchor remains a $330 fair value with $391 bull and $250 bear scenarios; that supports a Neutral stance on management quality specifically, with 72/100 thesis conviction. We would turn more cautious if succession disclosure failed to improve or if per-share value creation reversed, especially if equity stopped compounding while buybacks continued.

macro sensitivity

rates, fx, energy

Macro Sensitivity overview. Rate Sensitivity: High ($4.42T assets vs $362.44B equity; total liabilities/equity 11.21) · FX Exposure: Not disclosed (No geographic revenue mix in the available filings snapshot) · Commodity Exposure: Low direct (Industry is National Commercial Banks; no COGS commodity inputs disclosed).

Rate Sensitivity

High

$4.42T assets vs $362.44B equity; total liabilities/equity 11.21

Commodity Exposure

Low direct

Industry is National Commercial Banks; no COGS commodity inputs disclosed

Trade Policy Risk

Indirect

No tariff or China dependency disclosure in the snapshot; risk is second-order through clients

Equity Risk Premium

5.5%

Cost of equity 9.4%; dynamic WACC 10.1%

Cycle Phase

Late-cycle deceleration

2025 revenue growth +2.8%; implied Q4 2025 EPS $4.64 vs Q2 2025 EPS $5.24

Takeaway. The non-obvious point is how small macro changes can become very large in dollar terms for JPM because of balance-sheet scale, not because current profitability is weak. With $4.42T of assets at 2025 year-end and ROA of 1.3%, even modest rate, spread, or credit shifts can move earnings materially. A 1.0% move against the year-end asset base represents about $44.2B of balance-sheet exposure in absolute dollars, which is large relative to $57.05B of 2025 net income.

Interest-Rate Sensitivity Is the Primary Macro Variable

Region / Lens	Revenue % from Region	Primary Currency	Hedging Strategy	Net Unhedged Exposure	Impact of 10% Move
Consolidated reported revenue	100% reported in USD	USD	Reporting currency only; economic hedging not disclosed…	Not disclosed	Translation impact cannot be isolated from snapshot…
United States	Not disclosed	USD	Not disclosed	Not confirmed	Direct transaction FX impact not quantified…
Europe	Not disclosed	EUR/GBP/other not confirmed	Not disclosed	Not confirmed	Cannot quantify from available filings snapshot…
Asia-Pacific	Not disclosed	Local currencies not confirmed	Not disclosed	Not confirmed	Cannot quantify from available filings snapshot…
Latin America / Emerging Markets	Not disclosed	Local currencies not confirmed	Not disclosed	Not confirmed	Cannot quantify from available filings snapshot…
Other / Corporate-level translational exposure…	Not disclosed	Multiple / not confirmed	Natural or financial hedging not disclosed…	Not quantifiable	Use caution; disclosure gap prevents precise P&L estimate…

Takeaway. FX is clearly a real operating topic for a global bank, but this snapshot does not disclose the geographic revenue split, hedging program, or net unhedged exposure, so precision is not possible. The practical conclusion is that JPM’s reported macro sensitivity is far better evidenced by rates, balance-sheet size, and valuation than by any quantified FX line item in the available filings here.

Commodity Exposure Is Mostly Indirect Through Clients, Not Direct Through COGS

Trade Policy Risk Exists, but It Is a Credit-and-Activity Channel Rather Than a Tariff Cost Channel

Metric	Value
FY2023 revenue	$158.10B
Revenue	$177.56B
FY2025 revenue	$182.45B
Key Ratio	12.3%
EPS	$4.64
EPS	$5.24
DCF	$250
DCF	$391

Demand Sensitivity Shows Up Through Activity Normalization More Than Pure Consumer Volume

Indicator	Current Value	Historical Avg	Signal	Impact on Company
VIX	Not provided in source snapshot	Not provided	Not confirmed	Market volatility would affect trading and risk sentiment, but no current reading is available here.
Credit Spreads	Not provided in source snapshot	Not provided	Not confirmed	Would matter materially given $4.42T asset base and premium valuation, but current spread backdrop is not disclosed.
Yield Curve Shape	Not provided in source snapshot	Not provided	Not confirmed	Potentially the most important missing input for a bank; no current curve data or NII sensitivity is provided.
ISM Manufacturing	Not provided in source snapshot	Not provided	Not confirmed	Would inform corporate activity and loan demand, but no source value is available.
CPI YoY	Not provided in source snapshot	Not provided	Not confirmed	Inflation affects rate path and customer health, yet no CPI figure is supplied in the macro table.
Fed Funds Rate	Not provided in source snapshot	Not provided	Partially inferable only via 4.25% risk-free rate…	Rate path remains central to valuation; discount-rate inputs show 4.25% risk-free rate, 9.4% cost of equity, and 10.1% WACC.

Biggest risk. The key caution is that JPM is entering 2026 from a softer run-rate while still carrying very large balance-sheet leverage. The source data show implied Q4 2025 net income of $13.03B and implied Q4 2025 diluted EPS of $4.64, both below mid-year levels, while total liabilities to equity remain 11.21. If rates fall and credit costs normalize at the same time, the earnings slowdown could matter more than the current premium multiple implies.

Macro verdict. JPM is a qualified beneficiary of a still-orderly macro backdrop, but not a clean beneficiary of aggressive easing or economic slowdown. Strong profitability, $57.05B of 2025 net income, 31.3% net margin, and 15.7% ROE, gives it resilience, yet the most damaging scenario would be a combination of lower rates, wider credit spreads, and slower client activity because that would pressure both earnings power and the valuation premium of 2.81x TBV.

Our differentiated take is neutral-to-mildly bullish on macro sensitivity: the stock’s $330 base fair value implies 11.9% upside to the $306 price, but that upside is not large enough to ignore the softer late-2025 trend. We therefore keep a Neutral stance with only conviction 70/100, because JPM’s $4.42T asset base and 11.21 liabilities-to-equity ratio make it highly exposed to simultaneous rate and credit normalization. We would get more bullish if upcoming filings show reacceleration above the current +2.8% revenue growth rate or evidence that the implied Q4 2025 EPS of $4.64 was a temporary dip; we would turn more cautious if earnings continue to track near that lower exit rate.

See Product & Technology

See Supply Chain

quantitative profile

factor + mean reversion

Quantitative Profile overview. Momentum Score: 55 / 100 (House-derived from +1.4% EPS growth, +2.8% revenue growth, and softer implied Q4 2025 earnings; price-trend series not disclosed) · Value Score: 62 / 100 (14.6x P/E, 2.18x price-to-book, and DCF fair value of $330 vs $306 price) · Quality Score: 82 / 100 (31.3% net margin, 15.7% ROE, 1.3% ROA, goodwill equal to 14.5% of equity).

Momentum Score

55 / 100

House-derived from +1.4% EPS growth, +2.8% revenue growth, and softer implied Q4 2025 earnings; price-trend series not disclosed

Value Score

62 / 100

14.6x P/E, 2.18x price-to-book, and DCF fair value of $330 vs $306 price

Quality Score

82 / 100

31.3% net margin, 15.7% ROE, 1.3% ROA, goodwill equal to 14.5% of equity

Beta

0.94

Model-derived WACC input; below 1.0 indicates slightly lower market sensitivity than the broad market

Most important takeaway. JPM’s quant profile is stronger on quality and valuation than on pure growth or momentum. The hard evidence is that ROE was 15.7% and net margin was 31.3% in 2025, yet revenue growth slowed to +2.8% and net income growth was -2.4%, so the stock’s support comes from durability of earnings rather than accelerating operating momentum. That matters because the DCF still points to $330 per share versus a market price of $306, but the underlying quantitative case is a franchise-quality rerating argument, not a high-growth setup.

Factor	Score	Percentile vs Universe	Trend
Momentum	55 / 100	Estimated 55th percentile	Deteriorating
Value	62 / 100	Estimated 62nd percentile	Stable
Quality	82 / 100	Estimated 82nd percentile	Stable
Size	99 / 100	Estimated 99th percentile	Stable
Volatility	58 / 100	Estimated 58th percentile	Stable
Growth	45 / 100	Estimated 45th percentile	Deteriorating

Takeaway. The factor mix is quality-heavy rather than momentum-led. JPM screens best on profitability and scale, but the growth/momentum leg weakened as 2025 revenue growth slowed to 2.8%, net income growth turned -2.4%, and implied Q4 2025 EPS fell to about $4.64 from $5.07-$5.24 in the first three quarters.

Takeaway. A proper peak-to-trough study is not possible from the provided source data because only the current price of $306 is disclosed, not the full historical price series. For this pane, that means drawdown risk should be treated as an information gap rather than a quantified comfort signal.

Metric	Value
Fair Value	$306
Market capitalization	$810B
$10M example position	$10M
Net income	$57.05B
2025 year-end equity	$362.44B

Liquidity Profile

Asset	1yr Correlation	3yr Correlation	Rolling 90d Current	Interpretation
SPY	Not confirmed	Not confirmed	Not confirmed	Return series not provided; beta of 0.94 is the only market-sensitivity input available.
QQQ	Not confirmed	Not confirmed	Not confirmed	Cannot quantify tech correlation from source data.
XLF	Not confirmed	Not confirmed	Not confirmed	Sector ETF correlation requires historical returns that are absent from the snapshot.
BAC	Not confirmed	Not confirmed	Not confirmed	Peer correlation cannot be confirmed because peer price history is not included.
C	Not confirmed	Not confirmed	Not confirmed	Peer correlation cannot be confirmed because peer price history is not included.
WFC	Not confirmed	Not confirmed	Not confirmed	Peer correlation cannot be confirmed because peer price history is not included.

Takeaway. Correlation cannot be measured directly from the provided snapshot, so beta of 0.94 is the best available partial proxy for systematic market exposure. That suggests JPM is not obviously a high-beta outlier, but it does not replace a true rolling-correlation analysis versus SPY, XLF, or money-center bank peers.

Metric	Value
Current stock price of	$306
Net income	$14.64B
Net income	$14.99B
Net income	$14.39B
Net income	$13.03B
EPS	$4.64
EPS	$5.07-$5.24

Technical Profile

JPM Derived Factor Exposure
Chart data available in source JSON.

Biggest quant risk. The valuation and cash-flow signals are internally inconsistent, which lowers confidence in any precise quant timing call. Specifically, the DCF shows $330 per share of fair value versus a $306 stock price, but the Monte Carlo mean is -$263.34 with 0.0% upside, while reverse DCF implies a 30.8% FCF margin even though no audited cash flow statement is provided and computed operating cash flow is -$147.782B.

Quant verdict. The quantitative picture is constructive but incomplete: JPM scores well on quality and acceptable on value, with 31.3% net margin, 15.7% ROE, and a DCF fair value of $330 versus the current $306 price, but growth and momentum softened as revenue growth slowed to 2.8% and net income growth turned -2.4%. Our positioning call is Neutral with conviction 70/100; target price is $340, with bull/base/bear values of $391 / $330 / $250. This generally supports the fundamental thesis that JPM is a high-quality franchise, but it does not support a high-conviction timing trade until price-history, liquidity, correlation, and cash-flow evidence are more complete.

We see JPM’s quant setup as modestly bullish for the thesis, not aggressively bullish for timing, because the stock at $306 still sits about 11.9% below the DCF fair value of $330 while the company delivered $57.05B of 2025 net income and 15.7% ROE. The differentiated point is that this is a quality-plus-reasonable-value story rather than a momentum story: our derived factor work shows Quality 82 and Value 62, but only Momentum 55 and Growth 45. We would become more constructive if 2026 disclosures show earnings re-accelerating above the current 2.8% revenue growth pace and resolve the cash-flow inconsistency; we would turn more cautious if quarterly profit remains near the implied Q4 2025 net income of $13.03B and the stock continues to trade above 2.81x TBV without renewed growth support.

See Financial Analysis

options & derivatives

sentiment gauge

Options & Derivatives overview. 30-Day IV (%): Not confirmed (No option chain or live IV series in the source snapshot) · IV Rank (%): Not confirmed (1-year IV distribution data is not provided) · Put/Call Ratio: Not confirmed (No listed-options volume or open-interest feed included).

DCF Fair Value

$330

vs current price of $306; implied upside of 11.9%

Position

Neutral

conviction 61/100

Thesis Conviction

61/100

Moderate conviction due to strong fundamentals but incomplete options-market visibility

Most important takeaway. The key non-obvious issue is not an overheated options setup but a data-quality mismatch: JPM delivered very steady disclosed quarterly net income of $14.64B in Q1 2025, $14.99B in Q2 2025, and $14.39B in Q3 2025, yet the provided Monte Carlo output shows 0.0% probability of upside. For derivatives work, that means model-driven screens may overstate tail risk relative to the underlying earnings stability actually seen in the available filings.

Expiry	IV (%)	IV Change (1wk)	Skew (25Δ Put - 25Δ Call)
1M	Not confirmed	Not confirmed	Not confirmed
3M	Not confirmed	Not confirmed	Not confirmed
6M	Not confirmed	Not confirmed	Not confirmed
12M	Not confirmed	Not confirmed	Not confirmed

Metric	Value
Q1 2025 net income	$14.64B
Net income	$14.99B
Net income	$14.39B
Net income	$57.05B
Net income	$182.45B
Revenue	$20.02
Revenue	15.7%
EPS	31.3%

Implied Volatility Context: Fundamental Stability, But No Confirmed IV Read

· bear

$250

· bull

$391

Metric	Value
Net income FY2025	$57.05B
Diluted EPS FY2025	$20.02
Net margin FY2025	31.3%
ROE FY2025	15.7%
P/E	14.6x
Price-to-book	2.18x
Shareholders' equity FY2024	$344.76B
Shareholders' equity FY2025	$362.44B

Short Interest and Squeeze Risk: No Confirmed Crowded-Short Setup

Fund Type	Direction	Estimated Size	Notable Names	Evidence
Hedge Funds	Not confirmed	Not confirmed	Not confirmed	No 13F or options-holder detail in the source snapshot…
Mutual Funds	Not confirmed	Not confirmed	Not confirmed	No holder-level filing extract provided
Pension Funds	Not confirmed	Not confirmed	Not confirmed	Institutional ownership breakdown not disclosed…
Insurance / Asset Managers	Not confirmed	Not confirmed	Not confirmed	No 13F-derived positioning table included…
Index / Passive Vehicles	Long equity likely, but not confirmed from provided data…	Not confirmed	Not confirmed	Only shares outstanding and market cap are provided, not holder roster…

Biggest derivatives risk. The main caution is not a confirmed short squeeze or volatility spike; it is balance-sheet sensitivity. JPM ended 2025 with $4.06T of total liabilities against $362.44B of equity, equal to 11.21x liabilities-to-equity, so a macro or regulatory shock could still produce an outsized equity move even though reported earnings themselves were relatively steady.

Derivatives synthesis. Because no live option chain, IV term structure, or earnings-event pricing is disclosed, a true market-implied next-earnings move cannot be confirmed. Our analyst estimate, based on JPM’s steady 2025 quarterly net income range of $14.39B-$14.99B, 0.94 beta, and 11.9% upside to the $330 DCF fair value from the current $306 price, is a more moderate earnings move of roughly ±$18 to ±$23, or about ±6% to ±8%; we would place the probability of a >10% one-day move below 20%. In other words, absent contrary option data, we think the fundamentals argue for moderate rather than extreme event risk.

We are Neutral on JPM from a derivatives-thesis standpoint, but only with moderate conviction of 61/100, because the stock at $306 still sits below our deterministic fair value of $330 and far below the bull case of $391, while the bear case is $250. That asymmetry is favorable for defined-risk upside structures and supports a Neutral stance, even though direct option-market confirmation is missing. What would change our mind is either evidence that the live options surface is already pricing a much larger move than our estimated ±6% to ±8% earnings band, or new fundamental deterioration that breaks the recent stability in quarterly profit around $14.4B-$15.0B and materially weakens capital formation.

See Catalyst Map

governance & accounting

quality control

Governance & Accounting Quality overview. Board Independence: Not disclosed (Board roster and independence data are not provided in the source snapshot) · Avg Board Tenure: Not disclosed (Director tenure data are not provided in the source snapshot) · CEO Pay Ratio: Not disclosed (Executive compensation disclosure is not included in the provided snapshot).

Governance Score

Provisional score: accounting appears broadly coherent, but board, rights, and pay evidence are missing

Accounting Quality Flag

Watch

Revenue grew to $182.45B in 2025, but net income growth was -2.4% and cash-flow detail is unavailable

Balance-Sheet Risk Lens

11.21x

Total liabilities to equity from derived ratios; leverage amplifies the importance of controls

Most important takeaway. The non-obvious signal is that per-share results looked cleaner than absolute profit growth: diluted EPS was $20.02 in 2025 versus basic EPS of $20.05, but the same year showed net income growth of -2.4% while shares outstanding fell from 2.80B to 2.70B. That combination suggests reported EPS resilience was helped by capital management, not purely by stronger operating conversion, which matters for judging the quality of earnings support.

Name / Field	Independent	Tenure (years)	Key Committees	Other Board Seats	Relevant Expertise
Board roster disclosure	Not disclosed	Not disclosed	Not disclosed	Not disclosed	The provided source snapshot contains no director list or expertise matrix…
Independence status	Not confirmed	Not disclosed	Not disclosed	Not disclosed	No DEF 14A board-independence detail is included in the snapshot…
Committee composition	Not confirmed	Not disclosed	Audit / compensation / risk committees not provided…	Not disclosed	Committee membership cannot be assessed from the available filings snapshot…
Average tenure	Not confirmed	Not disclosed	Not disclosed	Not disclosed	Tenure data required for refreshment analysis are absent…
Chair / CEO split or lead director	Not confirmed	Not disclosed	Not disclosed	Not disclosed	Leadership structure is not described in the snapshot…

Shareholder Rights Assessment

Name	Title	Base Salary	Bonus	Equity Awards	Total Comp	Comp vs TSR Alignment
Chief Executive Officer	Not disclosed in provided snapshot	Not disclosed	Not disclosed	Not disclosed	Not disclosed	Cannot assess; pay disclosure absent
Chief Financial Officer	Not disclosed in provided snapshot	Not disclosed	Not disclosed	Not disclosed	Not disclosed	Cannot assess; pay disclosure absent
Other Named Executive Officers	Not disclosed in provided snapshot	Not disclosed	Not disclosed	Not disclosed	Not disclosed	Cannot assess; pay disclosure absent

Accounting Quality Deep-Dive

Dimension	Score (1-5)	Evidence Summary
Capital Allocation	4	Shares outstanding declined from 2.80B at 2024-12-31 to 2.70B at 2025-12-31 while shareholders' equity rose from $344.76B to $362.44B, indicating active capital management that supported per-share results.
Strategy Execution	4	Revenue increased from $177.56B in 2024 to $182.45B in 2025 and net margin remained 31.3%, though net income growth was -2.4%, so execution was strong but not flawless.
Communication	3	The numerical filings snapshot is coherent, but key governance disclosures such as board structure, compensation design, auditor commentary, and rights provisions are not available here, limiting transparency for this pane.
Culture	3	No direct culture or conduct disclosures are provided in the source snapshot. Stable quarterly profitability through most of 2025 is a modest positive, but culture cannot be robustly inferred from financials alone.
Track Record	4	2025 net income was $57.05B, ROE was 15.7%, ROA was 1.3%, and diluted EPS was $20.02. Those are strong outcomes, even with a year-over-year net income decline of 2.4%.
Alignment	3	Alignment is only partially visible. The share count reduction is shareholder-friendly, but CEO pay ratio, long-term incentive mix, ownership guidelines, and clawback specifics are not disclosed in the provided snapshot.

Key governance/accounting risk. The biggest caution is not an obvious accounting break, but the combination of high leverage (Total Liabilities to Equity of 11.21) and missing cash-flow detail. With only about 8.2% equity funding of year-end 2025 assets, even modest changes in reserve assumptions, asset marks, or valuation judgments can have an outsized effect on book value, and the absence of EDGAR cash-flow statements limits direct accrual-quality testing.

Governance verdict. Shareholder protection cannot be fully confirmed from the provided snapshot because board independence, committee composition, voting structure, proxy access, and executive pay terms are not disclosed. The overall read is therefore moderate quality with a Watch bias: accounting metrics are broadly coherent and profitability is strong, but the oversight architecture is too incomplete to justify a stronger governance endorsement.

Our differentiated take is that the more important signal here is accounting resilience, not proven governance excellence: diluted EPS of $20.02 was only $0.03 below basic EPS of $20.05, and goodwill stayed essentially flat at $52.73B year-end, which is mildly supportive for the thesis. That makes this neutral to mildly bullish on the stock’s quality profile, but only provisionally, because governance-critical items like board independence and CEO pay design are missing from the snapshot. We would turn more bullish if the DEF 14A confirms a majority-independent board and clearly long-term performance-linked pay; we would turn bearish if future filings show widening EPS dilution, weaker earnings conversion, or shareholder-rights provisions that entrench management.

See detailed valuation bridge, DCF assumptions, and method cross-check in the Valuation tab.

See Earnings Scorecard

value framework

greenwald / qarp

This pane applies a bank-adjusted Graham screen, a Buffett-style qualitative checklist, and a cross-check of earnings/book-based valuation against the provided DCF outputs. On the available filings and deterministic models, JPM screens as a high-quality but not classic deep-value bank: the stock at $306 is below the model base fair value of $330, but the premium 2.18x price-to-book and only moderate 10.6% margin of safety keep the conclusion at Neutral, moderate conviction rather than aggressive overweight.

Graham Score

2/7

Passes size and P/E; fails or is not confirmed on 5 criteria

Buffett Quality Score

B+

4 pillars scored 17/20 based on franchise durability and management quality

PEG Ratio

10.4x

P/E 14.6 divided by EPS growth 1.4%

Conviction Score

70/100

Good quality, only moderate undervaluation, bank-modeling noise

Margin of Safety

10.6%

Vs DCF fair value of $330 and price of $306

Quality-adjusted P/E

8.7x

P/E 14.6 divided by ROE/cost of equity spread factor of 15.7%/9.4%

Important takeaway. JPM looks optically expensive on book at 2.18x, but the more relevant signal is that its 15.7% ROE exceeds the modeled 9.4% cost of equity by 6.3 percentage points. That excess-return spread is the clearest evidence that the premium multiple is tied to franchise quality rather than simple balance-sheet leverage, which is why the stock can still be mildly undervalued even without screening as a traditional Graham bargain.

Criterion	Threshold	Actual Value	Pass/Fail
Adequate size	Large, established enterprise; for banks, clearly systemically relevant scale…	Market cap $810B; total assets $4.42T; revenue $182.45B…	PASS
Strong financial condition	Conservative balance sheet; bank-adjusted screen still requires strong capitalization and not excessive leverage…	Debt/Equity 0.74; Total Liabilities/Equity 11.21; shareholder equity $362.44B…	FAIL
Earnings stability	No deficit over a long period, typically 10 years…	2025 net income $57.05B; Q1-Q3 2025 net income $14.64B, $14.99B, $14.39B, but 10-year series not disclosed in snapshot…	FAIL
Dividend record	Uninterrupted dividends for at least 20 years…	Dividend data not disclosed in snapshot	FAIL
Earnings growth	Meaningful long-term EPS growth, traditionally at least one-third over 10 years…	Diluted EPS $20.02; EPS growth YoY +1.4%; long-term 10-year growth not disclosed…	FAIL
Moderate P/E	P/E <= 15	P/E 14.6	PASS
Moderate P/B	P/B <= 1.5 or justified by lower P/E	Price-to-book 2.18; P/E 14.6	FAIL

Biggest caution. Graham-style value investors should not ignore that JPM fails the cheap-on-book test with a 2.18x price-to-book and carries 11.21x total liabilities to equity. Those numbers do not make the stock uninvestable, but they do mean the thesis depends on sustained superior returns on capital rather than mean reversion to a classic bank discount.

Metric	Value
Buffett quality score	17/20
Revenue FY2025	$182.45B
Net income FY2025	$57.05B
Diluted EPS FY2025	$20.02
Q1 2025 net income	$14.64B
Q2 2025 net income	$14.99B
Q3 2025 net income	$14.39B
Understandable business score	4/5

Buffett Qualitative Assessment

Bias	Risk Level	Mitigation Step	Status
Anchoring to book value	High	Focus on ROE 15.7% versus cost of equity 9.4% before judging 2.18x P/B as too expensive…	Watch
Confirmation bias	Medium	Pair DCF upside with Monte Carlo and operating cash flow inconsistency to test the long case…	Watch
Recency bias	Medium	Do not extrapolate 2025 profitability blindly; revenue growth slowed to 2.8% and net income growth was -2.4%	Watch
Quality halo effect	High	Separate franchise admiration from valuation discipline; only 10.6% margin of safety exists to base fair value…	Flagged
Model overreliance	High	Downweight cash-flow-based outputs because operating cash flow is -$147.782B and Monte Carlo gives 0.0% upside for a bank…	Flagged
Base-rate neglect	Medium	Acknowledge that large banks usually rerate when ROE compresses, even if absolute earnings remain high…	Watch
Management worship	Low	Keep kill criteria tied to returns and valuation, not executive reputation…	Clear
Underweighting regulatory risk	High	Treat missing CET1 and capital-ratio disclosure as a real analytical gap, not a trivial omission…	Flagged

Metric	Value
Stock price	$306
Base fair value	$330
Bear value	$250
Bull value	$391
Margin of safety	10.6%
Price-to-book	2.18x
ROE vs cost of equity	15.7% vs 9.4%

Decision Framework

Metric	Value
Conviction score	70/100
Franchise durability	25%
Valuation support	20%
Capital allocation/per-share value	15%
Profitability / excess returns score	8/10
Net income FY2025	$57.05B
ROE FY2025	15.7%
Net margin FY2025	31.3%

Conviction Scoring by Pillar

Metric	Value	Interpretation
Current Price	$306	Reference market price as of Mar. 26, 2026…
DCF Fair Value	$330	Base-case intrinsic value from deterministic model…
Bull / Bear Values	$391 / $250	Scenario range frames upside and downside…
Upside to Fair Value	11.87%	Moderate rather than deep discount
P/E	14.6	Reasonable on earnings, not distressed
Price-to-Book	2.18	Premium multiple requires sustained excess returns…
ROE vs Cost of Equity	15.7% vs 9.4%	6.3-point spread supports premium valuation…
PEG	10.4x	Growth-adjusted valuation looks expensive because EPS growth is only 1.4%

Takeaway. JPM is inexpensive on earnings relative to quality, but not on growth. The stock’s 14.6x P/E looks acceptable because ROE is 15.7%, yet the 10.4x PEG reminds investors that near-term EPS growth is only 1.4%, so the thesis rests on durability and capital returns more than acceleration.

See the variant perception, moat debate, and catalyst map in the Thesis tab.

Synthesis. JPM passes the quality test but only partially passes the value test. The evidence justifies a 70/100 conviction because the stock offers moderate upside to $330 fair value and exceptional franchise quality, but the weak 2/7 Graham score, premium 2.18x P/B, and incomplete regulatory-capital disclosure prevent a higher score; I would raise conviction if valuation widened or if additional filings confirmed stronger capital headroom and tangible-book support.

See related analysis in

XVARY’s differentiated view is that JPM should be underwritten primarily as an excess-returns-on-equity story, not as a conventional cheap-bank story: with 15.7% ROE against a 9.4% cost of equity and a base fair value of $330 versus a $306 stock price, the setup is moderately bullish for the thesis even though the Graham screen only scores 2/7. What would change my mind is a clear deterioration in returns toward the cost of equity, or evidence from future filings that capital intensity and regulation are reducing the franchise’s ability to justify a premium 2.81x TBV multiple.

See detailed valuation, scenario weighting, and DCF assumptions

key value drivers

revenue engine

For JPMorgan Chase, the core valuation driver is not pure revenue growth; it is the market’s confidence that the firm can keep generating premium returns on equity from an enormous balance sheet through macro and credit cycles. With 2025 ROE of 15.7%, EPS of $20.02, and a still-premium 2.18x price-to-book, the stock is being valued as a high-quality compounder whose earnings durability matters more than top-line acceleration.

Proxy EPS sensitivity per 100bp ROE

$1.34

1.0pp ROE on $362.44B equity ≈ $3.6244B net income, or about $1.34/share on 2.70B shares

Historical beta to macro

0.94

From market-calibrated WACC inputs; near-market beta, but amplified by bank leverage

Bull/bear valuation spread

$147.61

DCF bull $391 vs bear $250 per share

Current ROE

15.7%

High enough to support JPM’s premium 2.18x price-to-book

Balance-sheet leverage

11.21x

Total liabilities to equity; macro and credit outcomes matter disproportionately

Quarterly earnings step-down

-$1.96B

Implied 4Q25 net income $13.03B vs 2Q25 peak $14.99B

Takeaway. The non-obvious point is that JPM’s valuation is being held up more by per-share capital compounding than by income growth. Even with net income growth of -2.4% in 2025, shares outstanding fell from 2.80B to 2.70B and estimated book value per share increased from $123.13 to $134.24, which helps explain why the market still supports a 2.18x price-to-book multiple.

The driver today: premium returns on a massive balance sheet

Trajectory: stable, but softening at the margin

Driver Component	2024	2025	What changed	Why it matters for valuation
Revenue	$177.56B	$182.45B	+2.8% YoY	Top-line growth slowed materially after 2024; valuation depends more on margins and returns than growth…
Net income	Not disclosed in snapshot table	$57.05B	Computed YoY growth -2.4%	Premium multiple needs earnings durability, not just revenue scale…
Diluted EPS	Not disclosed in snapshot table	$20.02	+1.4% YoY	Per-share earnings held up despite weaker net-income growth…
Total assets	$4.00T	$4.42T	+10.5% YoY	Larger balance sheet increases sensitivity to spreads, funding costs, and credit…
Shareholders' equity	$344.76B	$362.44B	+5.1% YoY	Capital base grew, but slower than assets; sustaining ROE is crucial…
Shares outstanding	2.80B	2.70B	-3.6% YoY	Buyback-driven denominator reduction supported EPS and book value per share…
Estimated book value per share	$123.13	$134.24	+9.0% YoY	Book compounding helps defend the current 2.18x price-to-book multiple…
Quarterly net income run-rate	Not disclosed in snapshot table	1Q25 $14.64B; 2Q25 $14.99B; 3Q25 $14.39B; 4Q25 implied $13.03B…	Late-year step-down	Shows the driver is still strong, but less robust than headline annual EPS suggests…

Takeaway. The deep-dive data shows that asset growth and capital growth are diverging: assets grew 10.5% in 2025 while equity grew 5.1%. That is exactly why sustaining a 15.7% ROE matters so much more to JPM’s valuation than whether revenue grew only 2.8% in the year.

What feeds this driver, and what it drives next

Factor	Current Value	Break Threshold	Probability	Impact
ROE durability	15.7%	Sustained ROE below 13.0%	25%	High
Annual net income power	$57.05B	Annualized net income below $50.00B	30%	High
EPS support	$20.02	Sustained EPS below $18.00	30%	High
Credit-cost normalization	1Q25 net charge-offs $2.3B; 4Q25 reserve build $2.1B…	Reserve builds above $2.1B for 2 consecutive quarters or charge-offs materially above the 1Q25 level without offsetting revenue…	35%	High
Book-value compounding	BVPS $134.24	Next year-end BVPS below $134.24	20%	Medium
Balance-sheet leverage	Liabilities/equity 11.21	Liabilities/equity above 12.0 without ROE improvement…	20%	Medium

· bear

$250

· bull

$391

Biggest risk. Credit normalization is the clearest threat to this driver because the earnings run-rate already showed stress late in 2025. The source set shows 1Q25 net charge-offs of $2.3B, a 1Q25 reserve build of $973M, and a 4Q25 reserve build of $2.1B; if those become recurring rather than episodic, the market will question whether 15.7% ROE is sustainable.

Confidence assessment. Confidence is moderate, because the filings strongly support JPM’s dependence on durable earnings and book-value compounding, but the precise rate-sensitivity mechanism is incomplete in this snapshot. Audited annual NII, deposit beta, deposit mix, loan mix, and CET1 are not confirmed here, so a dissenting view is that capital return or fee durability, rather than macro spread sensitivity, could prove to be the more important driver.

Our base case is that the stock’s key driver is sustainable return on equity, and on the current equity base every 100bp of sustainable ROE is worth about $1.34 of EPS and roughly $19.60 per share at the current multiple. That supports a $340 12-month target and $330 base fair value versus $306 today, with bull/base/bear values of $391 / $330 / $250 and thesis conviction of 71/100; that is bullish for the thesis, but we would change our mind if ROE moved durably below 13.0%, annualized earnings slipped below $50.00B, or audited funding and capital data showed materially weaker resilience than the current filings imply.

See Macro Sensitivity

capital allocation

buyback + dividend

Capital Allocation & Shareholder Returns overview. TTM BUYBACKS: Not disclosed (Repurchase dollars are absent from the provided EDGAR snapshot; visible evidence is shares outstanding falling from 2.80B to 2.70B in 2025.) · AVG BUYBACK PRICE VS INTRINSIC VALUE: Not disclosed (Average repurchase price is not provided; current stock price is $306 versus DCF fair value of $330.) · DIVIDEND YIELD: Not disclosed (Dividend per share is not included in the source snapshot, so yield cannot be confirmed.).

AVG BUYBACK PRICE VS INTRINSIC

$330

Average repurchase price is not provided; current stock price is $306 versus DCF fair value of $330.

2025 NET SHARE REDUCTION

-3.57%

Shares outstanding declined from 2.80B at 2024-12-31 to 2.70B at 2025-12-31.

2025 EQUITY GROWTH

+5.13%

Shareholders' equity increased from $344.76B to $362.44B in 2025.

EST. BVPS GROWTH

+9.02%

Estimated book value per share rose from $123.13 to $134.24 because equity grew while shares fell.

DCF FAIR VALUE

$330

Base case is 11.9% above the current price of $306.

BULL / BEAR VALUE

$391 / $250

Scenario range spans +39.8% upside to -18.3% downside versus current price.

POSITION / CONVICTION

70/100

conviction 70/100

Most important takeaway. JPM's capital allocation mattered more than the headline earnings trend suggests. Net income declined -2.4% in 2025, yet diluted EPS still grew +1.4% because shares outstanding fell from 2.80B to 2.70B, while shareholders' equity still rose by $17.68B. The non-obvious implication is that management preserved per-share compounding without depleting the capital base.

Year	Shares Repurchased	Avg Buyback Price	Intrinsic Value at Time	Premium / Discount %	Value Created / Destroyed
2021	Not disclosed	Not disclosed	Not confirmed	Not confirmed	Not confirmed
2022	Not disclosed	Not disclosed	Not confirmed	Not confirmed	Not confirmed
2023	Not disclosed	Not disclosed	Not confirmed	Not confirmed	Not confirmed
2024	Not disclosed	Not disclosed	Not confirmed	Not confirmed	Not confirmed
2025	0.10B net share reduction visible from year-end share count; gross repurchases not disclosed…	Not disclosed	Not confirmed at time of purchase; current DCF fair value is $330…	Not confirmed	Mixed by inference

Year	Dividend / Share	Payout Ratio %	Yield %	Growth Rate %
2021	Not disclosed	Not disclosed	Not disclosed	Not disclosed
2022	Not disclosed	Not disclosed	Not disclosed	Not disclosed
2023	Not disclosed	Not disclosed	Not disclosed	Not disclosed
2024	Not disclosed	Not disclosed	Not disclosed	Not disclosed
2025	Not disclosed	Not disclosed	Not disclosed	Not disclosed

Deal	Year	Price Paid	ROIC Outcome (%)	Strategic Fit	Verdict
No major deal disclosed in provided snapshot…	2021	Not disclosed	Not confirmed	Not confirmed	Insufficient evidence
No major deal disclosed in provided snapshot…	2022	Not disclosed	Not confirmed	Not confirmed	Insufficient evidence
No major deal disclosed in provided snapshot…	2023	Not disclosed	Not confirmed	Not confirmed	Insufficient evidence
No major deal disclosed in provided snapshot…	2024	Not disclosed	Not confirmed	Not confirmed	Insufficient evidence
Goodwill broadly stable at $52.62B-$52.73B through 2025…	2025	No material acquisition spend confirmed	Not confirmed	Likely low acquisition intensity	No evidence of major write-off

Cash Deployment Pattern: Visible Bias Toward Internal Capital Build + Buybacks

TSR and Per-Share Return Decomposition

Biggest caution. Buybacks may remain EPS-accretive but become less compelling economically if repurchases occur at elevated valuation. JPM trades at 2.81x TBV and $306 per share versus estimated year-end book value per share of $134.24; that makes repurchases likely book-value dilutive if done near current levels, even though the actual average repurchase price is not disclosed.

Verdict: Good. Management appears to be creating shareholder value through disciplined per-share capital allocation. The evidence is the combination of -3.57% share count, +1.4% diluted EPS growth despite -2.4% net income growth, and +9.02% estimated BVPS growth. It is not an Excellent rating because dividend transparency, repurchase pricing, and cash payout detail are missing, and the stock's premium valuation raises the hurdle for future buyback effectiveness.

We are mildly bullish on JPM's capital allocation because the measurable pieces are constructive: shares outstanding fell 3.57% in 2025, estimated book value per share rose 9.02%, and the stock still trades below our $330 base-case fair value by about 11.9%. Our position is Neutral with conviction 70/100 because the franchise is compounding capital per share even in a slower-growth year. We would change our mind if share count stopped declining while equity growth weakened, or if management kept buying aggressively at prices materially above intrinsic value without corresponding improvement in earnings power or regulatory capital flexibility.

See Earnings Scorecard

See Quantitative Profile

timeline

selected milestones

FAIR VALUE

$330

DCF base case vs $306 stock price

UPSIDE

+7.8%

Base case premium to Mar. 26, 2026 price

BULL / BEAR

$391 / $250

Deterministic scenario values

ROE

15.7%

Supports premium-bank analogy

P/TBV

2.18x

Market still paying for quality at scale

POSITION

Neutral

conviction 70/100

Analog Company	Era/Event	The Parallel	What Happened Next	Implication for This Company
JPMorgan itself	2024-2025 balance-sheet expansion and earnings normalization…	Assets grew from <strong>$4.00T</strong> at 2024 year-end to a <strong>$4.56T</strong> peak in 3Q25 before ending 2025 at <strong>$4.42T</strong>, while revenue still rose to <strong>$182.45B</strong>.	The pattern suggests a dominant funding and client franchise absorbing flows, but with late-year earnings cooling as implied 4Q25 net income fell to <strong>$13.03B</strong>.	This is a premium-franchise, late-cycle analog. The key question is not survival, but whether more assets convert into sustained returns or simply a larger balance sheet.
Morgan Stanley	Mature premium-bank phase	Useful analog for a large financial institution that wins a higher multiple because investors trust business mix and capital return more than raw revenue growth.	Historically, premium reratings became steadier but less explosive once the market already priced in quality; future stock moves depended on maintaining return metrics rather than narrating reinvention.	JPM at <strong>14.6x P/E</strong> and <strong>2.81x TBV</strong> looks similar in market psychology: upside likely comes from holding a premium, not from a sudden multiple step-change.
Goldman Sachs	Late-cycle earnings plateau at a high-quality franchise…	A top-tier financial institution can still trade well even when revenue grows but incremental earnings momentum softens.	When quarterly cadence loses momentum, investors typically stop paying for acceleration and instead value the company on normalized earnings power.	JPM's annual diluted EPS of <strong>$20.02</strong> implies 4Q25 diluted EPS of <strong>$4.64</strong>, below the first three quarters, so the stock may behave more like a quality compounder than a momentum trade.
Bank of America	Post-repair capital-return compounding	Once a large bank is no longer in repair mode, share count reduction can matter as much as underlying profit growth for per-share value creation.	In that pattern, book value growth and repurchases often drive investor returns more reliably than headline top-line acceleration.	JPM's share count fell from <strong>2.80B</strong> to <strong>2.70B</strong>, so the relevant analog is a scaled bank using excess capital to preserve EPS growth even if net income softens.
Wells Fargo	Premium multiple vulnerable to growth deceleration…	Large banks can keep premium valuations only as long as investors believe returns are durable and regulation or normalization will not erode earnings quality.	Once earnings momentum fades, the valuation premium can compress even if the franchise remains profitable and systemically important.	JPM's <strong>15.7% ROE</strong> justifies a premium today, but the implied 4Q25 slowdown and already-full <strong>2.81x TBV</strong> mean the analog warns against assuming endless multiple expansion.

Metric	Value
Revenue	$182.45B
Revenue	$177.56B
Revenue	$158.10B
Revenue growth	+2.8%
Net income	-2.4%
Net income	$14.64B
Net income	$14.99B
Net income	$14.39B

JPM Looks Like a Mature Franchise in Late-Cycle Normalization

Metric	Value
1Q25 goodwill	$52.62B
2Q25 goodwill	$52.75B
3Q25 goodwill	$52.72B
FY2025 goodwill	$52.73B
Net income	-2.4%
EPS	+1.4%
EPS	$20.02
2024 total assets	$4.00T

Recurring Historical Pattern: JPM Responds Through Scale, Capital Return, and Organic Compounding

See historical analogies

See fundamentals